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Bladder cancer constitutes one of the most prevalent cancers and is among the 
leading causes of cancer-related deaths in the United States. This work sought to better 
characterize and understand the role of the proto-oncogene anterior gradient 2 (AGR2) in 
bladder cancers. Immunohistochemical analysis of AGR2 expression in a range of 
bladder cancer specimens indicated that the expression of AGR2 decreases with an 
increase in the stage and grade of bladder cancers. The environmental carcinogens 
arsenic and cadmium (Cd2+) have been implicated in various cancers. This laboratory has 
demonstrated that arsenite (As3+) and Cd2+ can malignantly transform the bladder 
epithelium cell line UROtsa. This study therefore sought to determine AGR2 expression 
in six As3+ and seven Cd2+-transformed UROtsa cell lines in which real-time PCR and 
western blotting data indicated that AGR2 expression was increased in several of the 
transformed cell lines. Next AGR2 expression was evaluated in mouse heterotransplant 
tumors arising from the injection of the previously transformed UROtsa cell lines in 
athymic nude (Foxn1nu) mice. Results from real-time PCR analysis and 
immunohistochemistry on tumor samples demonstrated that AGR2 expression remained 
increased in most of the Cd2+ heterotransplants but was significantly increased in only a 
couple of the As3+ heterotransplants. UROtsa cells were further exposed to 2, 4, or 6 μM 
As3+ or to 1, 2, or 4 μM Cd2+ for up to 72 hours and real-time PCR analysis was 
performed to evaluate AGR2 expression. While AGR2 exhibited increased expression in 
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response to 48 hours As3+ exposure, expression was not induced to the same extent in 
Cd2+ exposed UROtsa cells. Spheroids containing cancer initiating cells (CICs) were 
generated from the transformed and the parent UROtsa cells and the expression of AGR2 
was determined. The results obtained suggested that there was an increase in the 
expression of AGR2 in all of the spheroids isolated from the As3+-transformed cells 
whereas some of the spheroids isolated from the Cd2+-transformed cells expressed high 
levels of AGR2 when compared to the spheroids isolated from the parent UROtsa cells.  
This laboratory has also shown that As3+ and Cd2+ can cause malignant 
transformation of a breast epithelial cell line, MCF-10A. Previous studies have shown 
that the expression of AGR2 promotes breast tumorigenesis in mice. This gene is known 
to play a role in promoting cellular transformation, tumor growth, and metastasis in 
various cancers. This study was interested in determining the expression level of AGR2 
in As3+ and Cd2+-transformed MCF-10A cells. Real-time PCR and Western analysis 
indicated that the expression of AGR2 was significantly increased in the MCF-10A cells 
transformed with As3+ when compared to the Cd2+-transformed cells. Exposure of the 
parent MCF-10A cells to 4, 8, and 16 μM As3+ for 48 hours resulted in a significant 
increase in the expression of AGR2 whereas exposure to Cd2+ did not increase the 
expression of AGR2, suggesting that As3+ has the potential to induce AGR2 in MCF-10A 
cells. In order to further investigate the effects of AGR2 expression on breast epithelial 
cells, MCF-10A cells were transfected with the AGR2 gene. Overexpression of AGR2 in 
the MCF-10A cells increased the ability of the cells to migrate faster in the wound 
scratch assay when compared to the blank vector transfected cells. In addition, MTT and 
scratch assays revealed increased growth and migration in the As3+-transformed cells 
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when compared to the parent MCF-10A cells and the Cd2+-transformed MCF-10A cells 
further implicating AGR2 in enhancing cell growth and migration. Treatment of the 
MCF-10A cells with the histone deacetylase inhibitor MS-275 and the demethylating 
agent, 5-Aza-2'-deoxycytidine (5-AZC) increased the expression of AGR2 suggesting 
that epigenetic modifications may be involved in regulating the expression of AGR2 in 
MCF-10A cells. These data also suggest that the expression of AGR2 in the MCF-10A 
cells may be regulated independently of the estrogen receptor status of the cells. Seeking 
to gain a better understanding of the relationship between AGR2 expression and breast 
cancer grade and stage, immunohistochemical staining was performed on a range of 
breast cancer specimens. Results showed elevated AGR2 expression with increasing 
grade of breast carcinoma. In conclusion, this study demonstrated the usefulness of 
AGR2 expression as a biomarker for bladder and breast cancers, further characterized the 
effect of AGR2 on the growth and migration of MCF-10A cells, and began to evaluate 







1.1 Bladder Cancer 
Bladder cancer is the fourth most common type of cancer among men (Jacobs, 
B.L., Lee, C.T., Montie 2010). Bladder cancer has previously been linked to cigarette 
smoking as well as various chemicals and occupational exposures. Bladder cancer is also 
of concern for women among whom it was estimated that 17,770 new cases would be 
diagnosed in 2010 (Jemal et al. 2009). The variances between risk for men and women 
are partially due to the fact that men were more likely to work in industrial jobs. One 
study reported that the R198 cell line, a model of transitional cell carcinoma, produced 
fewer tumors when transplanted into female or estrogen-treated male nude mice. This 
suggests the possibility that androgens have a role in the formation of bladder cancers 
which, in turn, may partially explain an increased prevalence of bladder cancers in men 
over women (Reid et al. 1984).  
Among the candidates for roles in bladder cancer is arsenic, which may be 
involved in bladder carcinogenesis. In addition, most diagnosed bladder cancers are of a 
papillary type, exhibiting low grade and stage. The concern is that most diagnosed 
bladder cancers also have a high likelihood of recurrence (Johansson and Cohen 1997).  
Bladder cancer risk has been associated with chemical and occupational carcinogen 




Schistosomiasis infections. Upon diagnosis, bladder cancer is classified as one of two 
main subtypes: superficial (non-muscle invasive) or muscle invasive (Droller 1998). 
1.1.1 Diagnosis of Bladder Cancer 
There are still several challenges to diagnosing and treating bladder cancer, 
among the most impactful are the need for better early detection methods. While most 
newly-diagnosed cases are superficial, they also have a high rate of recurrence within five 
years of initial diagnosis. This becomes more concerning as approximately 30% of 
recurrent bladder cancers are likely to become muscle-invasive (Lamm 1998). Together 
this stresses the challenge that bladder cancer is a high economic burden because of 
expenses due to treatment, complications, and long-term screening for recurrence 
(Bischoff and Clark 2009). Early detection is also a challenge because there are few 
known early disease symptoms for bladder cancer. The few early symptoms that a subset 
of patients experience include hematuria, frequent urination, and dysuria; all of these may 
be indicators of other pathologies besides cancers (Droller 1998). Diagnosing bladder 
cancer also relies upon cystoscopy, which is known to be unreliable in detecting flat 
carcinoma in situ (CIS) lesions (Droller 1998). This is of great significance as it is the 
CIS subtype that is most likely to progress to muscle-invasive disease.  
1.1.2 Current Bladder Cancer Treatments 
The treatment for most bladder cancers typically involves of transurethral 
resection of the bladder tumor (TURBT) followed by intravesical therapy with Bacillus 
Calmette-Guerin (BCG) (Jacobs, B.L., Lee, C.T., Montie 2010). For invasive bladder 
cancers, radical cystectomy is recommended though around 50% of patients will exhibit 




are desired as up to 40% of BCG treated cancers exhibit recurrence with a second BCG 
treatment providing a 35% chance of lasting success (Jacobs, B.L., Lee, C.T., Montie 
2010). Clearly, there is a need for more effective bladder cancer screening in hopes of 
diagnosing bladder cancers at earlier, more treatable stages. This has the potential to 
significantly reduce bladder cancer mortality in the future.   
1.2 Breast Cancer 
Breast cancer is the second leading cause of cancer-related deaths among women 
and constitutes 1 in 3 cancers diagnosed among United States women (Desantis et al. 
2011). Due to the high prevalence of breast cancer, there is a need to develop better 
prognostic as well as diagnostic markers of breast cancer that will aid in the treatment 
and diagnosis of the disease. Risk factors for breast cancer include those that can be 
modified as well as those that cannot be changed. Diet, lifestyle factors (i.e. exercise), 
and estrogen exposure are factors that may be controlled or changed in response to risk 
concerns. Among the risk factors that cannot be altered are age, race, genetic 
susceptibility, sex, familial cancer diagnoses, and history of other benign breast lesions. 
These risk factors also include the timing of the various stages of sexual development 
including the age at which a women undergoes menarche, has a first successful 
pregnancy (including the duration of breast-feeding), and the age at which a woman 
undergoes menopause (Kamińska et al. 2015).  
1.2.1 Diagnosis of Breast Cancer 
 Successful treatment of breast cancer depends on several factors, perhaps the most 
important of which is early diagnosis. One contributing factor to early detection involves 




clinical and self-breast examination. While such screening has been effective in 
identifying cases of breast cancer one major concern remains that generally by the time 
that a patient has a palpable tumor, as identified by breast examinations, most cancers 
have already progressed to a more advanced stage. Once screening identifies a patient of 
concern for breast cancer more diagnostic testing is done. This can involve utilizing 
additional imaging techniques (MRI or molecular breast imaging), sampling of breast 
tissue (biopsy), and testing for known tumor markers (Anderson et al. 2015; Nounou et 
al. 2015).   
1.2.2 Prognostic Markers for Breast Cancer 
Following initial diagnosis, it is imperative that each cancer is well-characterized 
for type and grade. Breast cancer is divided into either ductal or lobular subtypes, each of 
which may exhibit noninvasive or invasive phenotypes. Invasive ductal carcinoma 
constitutes 55% of breast cancers at the time of diagnosis (Makki 2015). Additionally, 
breast cancer is further subdivided using various molecular characteristics. The common 
molecularly classified subtypes include: luminal A, luminal B, HER2 positive, and basal-
like. The most common of these subtypes is luminal A, which makes up about 50% of all 
invasive breast tumors. Generally luminal A cancers express estrogen receptor (ERα) and 
the progesterone receptor (PR) and do not express HER2. Making up around 20% of 
invasive breast cancers are those of the luminal B subtype which do express ERα and PR 
but which exhibit HER2 expression to various degrees. Cancers of this subtype tend to 
have a range of responses to endocrine based treatments. About 15% of invasive breast 
cancers are of the subtype characterized by the overexpression of HER2 and a lack of 




probability of the cancer being higher in grade and having undergone metastasis to the 
lymph nodes. Finally, 15% of invasive breast cancers may be categorized as basal-like in 
exhibiting gene expression similar to basal epithelial cells. These have also become 
known as triple-negative breast cancers as they do not express ERα, PR, or HER2 while 
they do usually express the epidermal growth factor receptor (EGFR) and cytokeratins 5 
and 6. Characterization of these molecular subtypes is essential as it indicates which 
subtypes are likely to have a poorer prognosis and which will be either resistant or 
responsive to the various available therapies. This in turn will aid in deciding on which 
course(s) of treatment will be most advantageous for each breast cancer patient (Makki 
2015).  
1.2.3 Current Breast Cancer Treatments 
 Following diagnosis and characterization of breast cancer cases, a course of 
treatment must be decided upon. Generally treatment options include surgery and/or a 
combination of local or systemic treatments including chemotherapeutics, radiation, or 
endocrine therapies (Nounou et al. 2015). The age of the patient may also play a role in 
deciding treatment course as younger patients generally have unique concerns from those 
of older patients. Among these concerns are decreased fertility, longer survivorship and 
need for screening, and the potential impact that treatment may have on the patient’s 
ability to work and care for their families. Complicating these issues is the fact that, as 
younger women are not encouraged to undergo routine breast screening, it is more likely 
that younger patients with breast cancers are diagnosed with cancers advanced to higher 
stages (Partridge et al. 2012; Ademuyiwa et al. 2015). In metastatic breast cancers, 




a combination of endocrine therapies whereas other strategies may be needed if these are 
unsuccessful. (Reinert and Barrios 2015).  
1.3 Arsenic and Cadmium as Environmental Carcinogens 
This laboratory is interested in the identification of biomarkers that indicate 
potential human exposure to environmental agents, particularly heavy metals. Arsenic, a 
metalloid, and cadmium (Cd2+), a heavy metal, are known to be carcinogenic and 
previous studies have suggested a link between arsenic and Cd2+ exposure and breast 
cancer risk (Soh et al. 2011). In fact, arsenic and Cd2+ are two of the four metals known 
to be carcinogenic in humans, the other two metals being chromium and nickel (Ernst and 
Theriault 1984). Both arsenic and Cd2+ have been officially recognized as human 
carcinogens according to the International Agency for Research on Cancer (IARC) 
(Navarro Silvera and Rohan 2007). 
1.3.1 Arsenic Metabolism 
 As an environmental carcinogen, arsenic is found naturally in the soil and water 
of certain geographic areas. It can also be found as airborne particles when associated 
with industrial areas (Arita and Costa 2009). Arsenic exposure also occurs through the 
diet when eating seafood, mushrooms, poultry, and rice grown in contaminated areas 
(Jomova et al. 2011). Humans are generally exposed to arsenic through contaminated 
drinking water or occupational exposure in some industries (Navarro Silvera and Rohan 
2007). Generally arsenic is found in either organic or inorganic arsenic (iAs) forms and it 
is the inorganic form that has generally been shown to exhibit toxicity (Jomova et al. 
2011). The body metabolizes iAs through oxidation-reduction reactions and methylation. 




to bind to thiol groups or to glutathione which may also aid in detoxification when 
binding to a protein, effectively preventing further toxic reactions (Carter, Aposhian, and 
Gandolfi 2003; Luster and Simeonova 2004).  
 Most commonly, arsenic is ingested as a trivalent inorganic species. Arsenic can 
be secreted in urine but some species have been known to accumulate in the body for as 
long as several months before being cleared. Inorganic arsenic has two primary forms: 
arsenite (As3+) or arsenate (As5+). Glutathione (GSH) is responsible for the conversion of 
As5+ into As3+ after which methylation can occur to generate organic arsenic forms 
(Jomova et al. 2011). During metabolism both forms can be either di- or tri-methylated. 
Arsenite can be bound to three thiol groups by GSH or converted to monomethyl arsenic 
(MMA) or dimethyl arsenic (DMA) by arsenic methyltransferases (Figure 1).  
 
Figure 1 – The Metabolism of Inorganic Arsenic. Reproduced from Jomova et al. 2011 




1.3.2 Arsenic Toxicity and Carcinogenesis 
 With exposure to even low levels of arsenic, risk of several forms of cancer have 
been shown. These include cancers of the skin, bladder, liver, kidney, and lung (Arita and 
Costa 2009). Several sources have demonstrated that contaminated drinking water can 
lead to cancer, including specifically bladder cancer (Smith et al. 1992; Steinmaus et al. 
2000). Arsenic is capable of causing carcinogenic changes through several mechanisms, a 
couple of which are known to include changes in cell differentiation and growth. In 
addition, iAs exposure has been demonstrated to induce chromosomal abnormalities 
(Navarro Silvera and Rohan 2007). Other potential mechanisms include interference with 
DNA repair, alteration of DNA methylation patterns, direct cytotoxicity, the induction of 
oxidative stress, and influence on signaling pathways (Pershagen 1981; Kitchin and 
Wallace 2008; Arita and Costa 2009). 
1.3.3 Arsenic and Bladder Cancer 
 In bladder cells, arsenic is able to increase cell proliferation through the 
stimulation of the mitogen-activated protein kinase (MAPK) and extracellular-signal 
related kinase (ERK) signaling pathways (Luster and Simeonova 2004). This may 
contribute to the uncontrolled growth which is definitive of cancer. Furthermore, arsenic 
exposure has been well-established as a link to bladder cancer occurrence through several 
epidemiological studies. Looking at several of these studies, there is still some debate as 
to the levels of iAs exposure that increase the probability of bladder cancer and even 
whether low doses are linked to bladder cancer at all. Taken together however, it appears 




to bladder cancer incidence occurs, especially when combined with smoking (Letašiová 
et al. 2012; Cohen et al. 2013; Saint-Jacques et al. 2014).  
1.3.4 Arsenic and Breast Cancer  
 The relationship between arsenic and breast cancer has yet to be fully elucidated 
but from what is known, it is a complex interaction. One study has demonstrated that in 
utero exposure to arsenic impacts mammary tissue development and increases the risk of 
developing breast cancer later in life (Parodi et al. 2015). On the other hand, arsenic 
trioxide has been used in some attempts to treat breast cancer, particularly as a means to 
re-establish sensitivity to endocrine therapy (Zhang et al. 2011) or paclitaxel 
(Bakhshaiesh et al. 2015) and to work with mammalian target of rapamycin (mTOR) 
inhibitors to increase anti-tumor activity (Guilbert et al. 2013). Arsenic has been shown 
to stimulate the epithelial to mesenchymal transition (EMT) in breast cells, with the 
possible generation of a cancer stem cell population within transformed cells (Xu, Erik J. 
Tokar, and Waalkes 2014). 
 Further complicating the relationship between arsenic and breast cancer is the fact 
that arsenic is known to act as a metalloestrogen to disrupt normal endocrine signaling, 
with serious repercussions for breast cancers. It appears that arsenic can have both ERα-
dependent and –independent mechanisms of action, either of which may induce or impact 
breast cancers (Davey et al. 2007; Xu, Erik J. Tokar, and Waalkes 2014). One study in 
MCF-10A cells has demonstrated that arsenic exposure can transform ERα-negative 
breast epithelium into a cell line exhibiting the common features of triple-negative breast 
cancers, which usually exhibit poor prognosis and are resistant to chemotherapeutic 




1.3.5 Cadmium Metabolism 
 Exposure to Cd2+ generally results from cigarette smoking, occupational exposure 
(including metal industries), or through the diet (Navarro Silvera and Rohan 2007; Arita 
and Costa 2009). Of particular concern in the case of Cd2+ exposure is that the human 
body is not equipped to metabolize Cd2+, therefore it accumulates in the body and it is not 
easily secreted (Arita and Costa 2009; Martinez-Zamudio and Ha 2011). Cadmium can 
be retained in the body for longer than 20 years before it is secreted. Generally 
detoxification occurs via binding to proteins that contain thiol groups (such as GSH), 
which leads to the production of oxidative stress and can eventually alter gene expression 
patterns, arresting the cell cycle, inducing differentiation and immortalization, or 
triggering apoptosis (Martelli et al. 2006). One of the more well understood proteins 
known to aid in the detoxification of Cd2+ are those in the metallothionein superfamily. 
Metallothioneins contain multiple cysteine amino acids which give them a very high 
affinity for certain metals, including Cd2+. While binding to metallothionein, Cd2+ is 
prevented from undergoing further reactions, resulting in detoxification (Klaassen, Liu, 
and Choudhuri 1999; Klaassen, Liu, and Diwan 2009).  
1.3.6 Cadmium Toxicity and Carcinogenesis 
 Cadmium is believed to stimulate carcinogenesis through various genotoxic 
means: apoptosis inhibition, single-stranded DNA breaks, DNA repair inhibition, 
mismatch repair inactivation, stimulation of oxidative stress, interference with cell-cell 
connections, and proto-oncogene activation (Navarro Silvera and Rohan 2007; Arita and 
Costa 2009; Feki-Tounsi and Hamza-Chaffai 2014). Of obvious interest when 




protein p53, through a mechanism that appears to involve interference with the zinc-
binding sites which usually activate p53 (Hartwig 2013). Another study noted differences 
in the p53 response to Cd2+ depending on the concentration; lower doses of Cd2+ 
appeared to activate p53 (possibly leading to apoptosis) through the generation of 
reactive oxygen species (ROS) and stabilization of p53 structure. On the other hand, 
higher doses of Cd2+ appeared to inhibit p53 activity by inducing conformational changes 
which interfere with the ability of p53 bind to zinc preventing p53 activation (Méplan, 
Mann, and Chem 1999). Cadmium exposure has also been linked to other diseases 
including kidney and cardiovascular disease as well as effects on lung and mammary 
tissue (Satarug et al. 2010).  
1.3.7 Cadmium and Bladder Cancer 
 Epidemiological studies have indicated that there is a link between Cd2+ exposure 
and bladder cancer risk (Feki-Tounsi and Hamza-Chaffai 2014). In Belgium, one study 
demonstrated a connection between higher blood Cd2+ levels and increased risk of 
bladder cancer. The odds ratio (OR) for Cd2+ exposure was 8.3 with a 95% confidence 
interval (CI) once adjusted for age, gender, and occupational exposures to either aromatic 
amines or polycyclic aromatic hydrocarbons. When also controlled for smoking, the OR 
for Cd2+ remained significant at 5.7 (Kellen et al. 2007). One study evaluated the 
interactions between arsenic and Cd2+ in relation to bladder cancers using exposed 
Tunisian men. The results suggested that there was an increased blood Cd2+ 
concentrations in bladder cancer patients, especially smokers where blood Cd2+ levels 
were nearly doubled compared to non-smokers once controlled for other confounding 




compared to participants also exhibiting increased blood As3+ levels which exhibited a 
2.10 OR (Feki-Tounsi et al. 2013). At least one other study compared urine Cd2+ levels 
between controls and patients with transitional cell carcinoma of the bladder. Results 
indicated a correlation between increased Cd2+ concentrations and the presence of 
transitional cell carcinoma. This study determined the effect of Cd2+ to have an OR of 
7.11 for urinary Cd2+ when controlled for total protein (95% CI). It is also interesting to 
note that nearly all of the Cd2+ found in the urine samples of this study were bound to 
metallothionein (Wolf, Strenziok, and Kyriakopoulos 2009). 
1.3.8 Cadmium and Breast Cancer 
 High urinary Cd2+ levels have been linked to an increased risk for breast cancers, 
in part due to the ability of Cd2+ to function as a metalloestrogen. A meta-analysis of 
case-control and cross sectional studies found a combined OR of 2.24 for Cd2+ levels in 
breast cancer cases comparing participants with the highest Cd2+ levels to those with the 
lowest  (Larsson, Orsini, and Wolk 2015). As a metalloestrogen, Cd2+ is known to bind to 
and activate ERα, resulting in the activation of several signal transduction pathways 
which could contribute to the unregulated growth of mammary cells (Byrne et al. 2013). 
This ERα activation would potentially have further repercussions in breast cancers, 
affecting the ability of the tumor to respond to some treatments, especially those that are 
endocrine or hormone based.  
1.4 Anterior Gradient 2 
1.4.1 AGR2 Function 
Originally identified in Xenopus laevis, anterior gradient 2 was found to be 




patterning (Aberger et al. 1998). The human analog of the anterior gradient 2 (AGR2) 
gene is of great interest due to the roles it performs in the endoplasmic reticulum stress 
response and as a proto-oncogene in various human cancers. One primary known 
function of AGR2 is that it is a member of the protein disulfide isomerase (PDI) family of 
chaperone proteins (Persson et al. 2005; Park et al. 2009; Higa et al. 2011; Shishkin et al. 
2013).  
Primarily, AGR2 is known to function within the endoplasmic reticulum, though 
there is evidence to suggest that it is secreted in gastrointestinal mucus (Park et al. 2009; 
Bergström et al. 2014). Anterior gradient 2 is normally expressed in mucus-secreting 
cells such as that of the lung, trachea, stomach, colon, prostate, and small intestine where 
it is known to play a role in mucin production and secretion (Missiaglia et al. 2004). 
Additional functions of AGR2 are still somewhat unclear, beyond its role as a PDI as part 
of the cellular response regulating endoplasmic reticulum stress (Higa et al. 2011). One 
role for AGR2 that is of great interest for this project is that of a proto-oncogene in 
various cancers.  
One very recent study has begun to clarify roles for extracellular or plasma 
membrane localized AGR2. This study found that growth, migration, and cell cycle 
progression were all increased in the MCF-7 cell line in response to the presence of 
extracellular AGR2. They were also able to demonstrate that ERα can signal for AGR2 to 
relocalize from the endoplasmic reticulum to the plasma membrane. The same study 
showed that AGR2 interacts extracellularly with ERα and the insulin-like growth factor 1 
(IGF-1) receptor and that these interactions influence cell growth, migratory ability, 




revealed that extracellular AGR2 can influence extracellular matrix function, leading to 
changes in the tumor microenvironment. Here AGR2 was also shown to disrupt contacts 
between cells by inducing the loss of E-cadherin (Fessart et al. 2016).  
1.4.2 AGR2 as a Protein Disulfide Isomerase 
 Human AGR2 was identified as a member of the PDI family in 2005. As a 
member of this family, the AGR2 gene is known to have some of the common 
characteristics of PDIs, including a CXXC, or thioredoxin, motif which plays a role in 
oxidation and reduction reactions, enabling AGR2 to interact with misfolded proteins by 
forming disulfide bridges. Protein disulfide isomerases are able to oxidize, reduce, or 
isomerize these disulfide bonds to correct improperly folded domains in client proteins 
(Persson et al. 2005). Another common property of PDIs is a localization to the 
endoplasmic reticulum. In AGR2 endoplasmic reticulum localization is accomplished by 
the presence of a KTEL retention sequence, which is similar to the more well-understood 
and frequently seen KDEL sequence (Fourtouna et al. 2009; Park et al. 2009).  
1.4.3 AGR2 Protein Interactions and Effects 
 While performing it’s normal function as a PDI, AGR2 is known to interact with 
mucin 2 (MUC2), preparing it for secretion and maintaining endoplasmic reticulum 
homeostasis (Park et al. 2009; Bergström et al. 2014). Anterior gradient 2 is also known 
to bind and act as a molecular chaperone for reptin (Maslon et al. 2010; Chevet et al. 
2013). Reptin functions as a tumor repressor and is known to impact the progression of 
cancer cells to metastasis (Kim et al. 2006). While most of the exact mechanisms have 
yet to be studied, AGR2 has been demonstrated to impact the expression of several 




cancer progression. Most of these cancer-associated roles seem to correspond to 
extracellular or plasma membrane-associated AGR2. Perhaps the most obvious link to 
cancer is the ability of AGR2 to silence p53 expression, interfering with the cells ability 
to respond to DNA damage and initiate repair pathways (Pohler et al. 2004). One study 
has suggested that Cyclin D1 may be activated downstream of AGR2 resulting in 
increased cell growth and progression through the cell cycle (Vanderlaag et al. 2010).  
Extracellular AGR2 has been shown to bind C4.4A and dystroglycan, suggesting 
a possible role for AGR2 in metastasis (Fletcher et al. 2003). One study demonstrated 
that AGR2 can activate YAP1 via dephosphorylation resulting in the activation of the 
hippo pathway and the induction of AREG expression. In turn, AREG has been shown to 
have a role in tumorigenesis and the regulation of cell growth (Dong et al. 2011). In 
pancreatic cancer, AGR2 has been shown to be an indicator of poor prognosis and AGR2 
upregulation can increase metastasis through the post-transcriptional regulation of 
Cathepsin B and D expression (Ramachandran et al. 2008; Dumartin et al. 2011; 
Brychtova et al. 2014). It has also been reported that AGR2 has the ability to enable 
cancer cells to escape normal cell death mechanisms through signaling mechanisms 
which increase survivin expression (Vanderlaag et al. 2010). Additionally, AGR2 appears 
to interact with ERα, which has implications specifically in hormone-responsive cancers 
(Vanderlaag et al. 2010).  
1.4.4 AGR2 Gene Regulation 
The regulation of AGR2 is not completely understood but there are a few 
mechanisms known to regulate AGR2 expression. Most notably, the inositol requiring 1 




response are known to induce AGR2 expression (Higa et al. 2011). In response to 
extracellular stimuli, the ERK pathway has been shown to induce AGR2 expression 
(Zweitzig et al. 2007). There have also been a few studies which suggested the possibility 
that As3+ could induce AGR2 expression. These related studies have demonstrated that in 
utero exposure of mice to iAs resulted in offspring exhibiting increased ERα expression 
and increased expression of related genes, including AGR2 (Liu et al. 2007; Shen et al. 
2007; Liu et al. 2008). In specific relation to cancers, AGR2 is known to be induced by 
ERα and has been shown to be repressed by erb-b2 receptor tyrosine kinase 3 (ErbB3) in 
prostate cancers (Vanderlaag et al. 2010; Zhang et al. 2010; Verma et al. 2012; Salmans, 
Zhao, and Andersen 2013). One more recent study was able to demonstrate that IGF-1 
can induce AGR2 expression using an estrogen-response element (ERE) and an activator 
protein 1 (AP-1) site on the AGR2 promoter. This mechanism was shown to involve the 
ERK, protein kinase B (AKT), and ERα signaling pathways. The IGF-1-mediated 
induction of AGR2 occurred either with or without estrogen but was demonstrated to 
require ERα (Li et al. 2015). 
1.4.5 AGR2 in Cancers 
The anterior gradient homolog 2 protein is known to be expressed in a wide 
variety of cancers including carcinomas of the ovaries, colon, thyroid, pancreas, breast, 
prostate and lung (Liu et al. 2005; Zhang et al. 2005; Bu et al. 2011; Darb-Esfahani et al. 
2012; Pizzi et al. 2012; Kani et al. 2013; Di Maro et al. 2014; Riener et al. 2014). The 
AGR2 protein is also known to be involved in various tumor associated pathways which 
include those involved in tumor growth, cellular transformation and metastasis (Liu et al. 




AGR2 on the progression of cancer include the previously discussed interactions it has 
with Cathepsins B and D, C4.4a, dystroglycan, yes-associated protein 1 (YAP1), and 
amphiregulin (AREG) (Fletcher et al. 2003; Wang, Hao, and Anson W Lowe 2008; Dong 
et al. 2011; Dumartin et al. 2011). 
Regulation of the epithelial to mesenchymal transition (EMT) is another possible 
role of AGR2 (Bu et al. 2011; Ma et al. 2015; Mizuuchi et al. 2015). This is of significant 
interest as cells with the ability to undergo EMT are characteristic of metastatic cancers. 
A connection between AGR2 and EMT seems to have been originally suggested in Bu et 
al. 2011, a study which determined that AGR2 is upregulated in prostate cancers. 
Concurrently it was observed that in AGR2 overexpression and knockdown studies, a 
significant effect occurred in the ability of the cells to proliferate and metastasize. These 
changes exhibited characteristics similar to what is seen in the actions of some 
transcription factors known to have roles in stimulating EMT during both development 
and in various cancers (Bu et al. 2011). Another study demonstrated that AGR2 
expression can be regulated by known EMT inducers in a subset of prostate cancers 
(Mizuuchi et al. 2015). An AGR2-involving EMT pathway was also demonstrated to 
exist in glioblastoma cases (Xu et al. 2015).  
1.4.6 AGR2 and Bladder Cancer 
 Studies have suggested that while the bladder normally expresses AGR2, it does 
not usually secrete AGR2 in the urine or express AGR2 on the cell surface. This suggests 
that AGR2 typically remains localized to the endoplasmic reticulum in normal bladder 
epithelium. On the other hand, bladder cancers have been shown to exhibit lower cellular 




secreted AGR2 in urine specimens. This suggests that overall AGR2 expression may be 
relatively unchanged, rather it is the localization of AGR2 that is important for indicating 
the presence of bladder cancer. It appears that rather than being retained in the 
endoplasmic reticulum, AGR2 becomes secreted in the presence of bladder cancer. The 
presence of secreted AGR2 in the blood or urine is therefore a potential biomarker for 
bladder cancer among other cancers (Ho et al. 2016). 
1.4.7 AGR2 in Breast Cancer 
In breast cancer, AGR2 is known to be estrogen receptor responsive and is 
overexpressed in estrogen receptor positive (ERα-positive) breast cancers (Thompson and 
Weigel 1998; Fletcher et al. 2003; Pohler et al. 2004; Innes et al. 2006; Salmans, Zhao, 
and Andersen 2013). While AGR2 expression has been demonstrated to have significant 
prognostic meaning in ERα-positive breast cancers, less is known about the effect of 
AGR2 in ERα-negative breast cancers. It is of interest to note that, though not well 
understood, AGR2 has been shown to act through ERα-independent mechanisms 
(Zweitzig et al. 2007).  It has been shown that AGR2 may play a role in the metastasis of 
breast cancer and is an indicator of poor prognosis (Fletcher et al. 2003; Fritzsche et al. 
2006; Innes et al. 2006; Barraclough et al. 2009; Lacambra et al. 2015). Furthermore, 
AGR2 is known to increase cell proliferation and survival in breast cancers through 
interactions with cyclin D1, ERα, and survivin (Vanderlaag et al. 2010). Research has 
also linked AGR2 expression to Tamoxifen resistance in breast cancers (Hrstka et al. 






1.4.8 AGR2 and the Unfolded Protein Response 
 It is known that AGR2 plays a role in the cellular response to endoplasmic 
reticulum stress. The pathway responsible for initiating AGR2 in response to stress is the 
unfolded protein response. In the presence of cellular stress such as misfolded proteins, 
cells can initiate signaling through the activating transcription factor (ATF6), double 
stranded RNA-activated protein kinase (PRK)-like endoplasmic reticulum kinase 
(PERK), and inositol requiring 1 (IRE1) transmembrane proteins. The downstream 
signaling pathways of ATF6 and IRE1 are known to initiate AGR2 transcription and 
translation. AGR2, in turn binds misfolded client proteins via disulfide bonds (Higa et al. 
2011).  
1.5 Experimental Models 
1.5.1 UROtsa 
 UROtsa is a model of transitional cell carcinoma arising from SV40 large T 
antigen-immortalized-human urothelial cells. The UROtsa cell line was initially cultured 
from the urothelial lining of a 12-year old female. This new cell line was therefore 
immortalized but did not display characteristics consistent with tumor cells as they did 
not grow colonies when cultured on soft agar plates or form tumors upon injection into 
nude mice (Petzoldt et al. 1995). This lab has further evaluated the UROtsa cell line and 
determined that it is a good model for human urothelium and useful for the evaluation of 
the stress response and responses to environmental toxicants, including As3+ or Cd2+. In 
this study UROtsa cells were cultured in serum-free media and were demonstrated to 
form cell layers with features consistent with in situ urothelium, particularly those of the 




UROtsa cell line was transformed by exposure to 1 μM sodium arsenite (NaAsO2) or 1 
μM cadmium chloride (CdCl2) so that six As3+ and seven Cd2+-transformed cell lines 
were created. These cell lines were also injected into nude mice and allowed to form 
tumors. Together, the cell lines and tumors have formed a model for arsenic and Cd2+-
induced bladder cancers, which allows for the study of and comparison between the in 
vitro cultured transformed cell lines and their corresponding heterotransplant tumors, a 
more in vivo approach (Sens et al. 2004). Upon microarray analysis comparing the 
transformed cell lines to the non-transformed UROtsa, several differentially expressed 
genes were identified and may be investigated as potential biomarkers for As3+ and Cd2+-
induced bladder cancers. (Garrett et al. 2014).  
1.5.2 MCF-10A 
 The MCF-10A cell line is a human breast epithelial cell line, obtained from a 36-
year old Caucasian female with fibrocystic disease. MCF-10A is known to have 
undergone spontaneous immortalization and is not tumorigenic when injected into nude 
mice. Previously, the MCF-10A cell line was obtained by this laboratory and transformed 
by exposure to 1 μM NaAsO2 or 1 μM CdCl2. These As3+ and Cd2+-transformed cell lines 
were evaluated for an ability to grow in soft agar, indicating anchorage independent 
growth. Further characterization has demonstrated that the MCF-10A parent cell line and 
corresponding As3+ and Cd2+-transformed cell lines are a good model of metal-induced 
breast cancers (Soh et al. 2011).  
1.6 Intent and Goals of Study 
This study was intended to answer several questions aimed at improving 




demonstrate whether AGR2 has a role in bladder cancers and in breast cancers. This 
study also sought to gain a better understanding about the function of AGR2 in these 
cancers and to elucidate a possible mechanism by which AGR2 expression is regulated in 
cancers. These objectives stem from the hypothesis that the proto-oncogene AGR2 is a 
useful biomarker for breast and bladder cancers resulting from exposures to As3+ and 
Cd2+. Anterior gradient 2 is expressed in the normal bladder urothelium and it has been 
shown that the expression of AGR2 decreases within the cell while AGR2 secretion 
increases as the grade and stage of urothelial cancers increases (Ho et al. 2016). 
Immunohistochemical analysis was utilized to determine the expression of AGR2 in 
human bladder cancer specimens and to evaluate whether the expression of AGR2 could 
be used as a prognostic or diagnostic marker for bladder cancer. This laboratory has 
developed an in-vitro model of bladder cancer by transforming the normal urothelial cell 
line UROtsa with As3+ and Cd2+. A microarray analysis of the transformed cells showed 
that transformation of the UROtsa cells with As3+ increased the expression of the proto-
oncogene AGR2 and this study attempted to validate the microarray results using real-
time PCR analysis and western blotting. The increased AGR2 expression seen in 
transformed UROtsa cell lines could be attributable to the differences between in vitro 
cell culture models and in vivo tissue or animal models. The expression of AGR2 in 
tumor heterotransplants derived from the As3+ and Cd2+-transformed UROtsa cell lines 
was determined in order to evaluate whether the effect of As3+ or Cd2+ would remain or 
increase in an in vivo model. This led to the question of whether short term As3+ or Cd2+ 




Previously this laboratory has also shown that chronic exposure of the normal 
breast epithelial cell line MCF-10A to As3+ or Cd2+ results in the transformation of these 
cells (Soh et al. 2011). This prompted investigation into whether AGR2 expression was 
differentially expressed in the MCF-10A model of metal induced breast cancers using 
real-time PCR analysis and western blotting. Similar to the previous evaluation of AGR2 
in the bladder, it was next determined whether short term exposure to As3+ or Cd2+ could 
induce the expression of AGR2 in the parent MCF-10A cells. Previous studies have 
suggested that overexpression of AGR2 can increase the growth and migratory potential 
of breast cancer cells, therefore this study sought to determine whether the 
overexpression of AGR2 in the MCF-10A cells would increase the growth and migratory 
potential of these cells. For this purpose, the parent MCF-10A cells were transfected with 
the AGR2 gene and the growth rate and migratory potential of the parent, As3+-and Cd2+-
transformed MCF-10 cells and the AGR2 transfected cells were determined using the 
MTT and the wound scratch assays.  
Other studies have shown that expression of AGR2 is associated with the estrogen 
receptor alpha (ERα) status of the breast tumors, therefore was asked whether ERα 
expression is present in the MCF-10A model using real-time PCR analysis. Since 
methylation and histone modification are two of the mechanisms that are involved in the 
regulation of gene expression, this study determined whether either of these mechanisms 
could be responsible for the regulation of AGR2 in MCF-10A cells. To address this 
question, MCF-10A cells were treated with the demethylating agent 5’-azacytidine (5-
AZC) or the histone deacetylase (HDAC) inhibitor, Entinostat (MS-275) after which real-




can secrete AGR2 and therefore this study attempted to determine whether AGR2 is 
secreted by MCF-10A cells. Immunohistochemical localization of AGR2 in a variety of 
different breast cancers was also determined to evaluate whether the expression of AGR2 







2.1 Cell Culture 
 UROtsa cells were obtained from from the American Type Culture Collection 
(ATCC) (Rockville, MD) and were grown in Dulbecco’s Modified Eagles Medium 
(DMEM) (Sigma-Aldrich, St. Louis, MO; D5523) supplemented with 5% (v/v) FBS 
(Gibco/Invitrogen, Grand Island, NY; 16000-044). Cells were supplied with fresh media 
every 3 days or upon confluency. Subculture was also completed upon confluency using 
0.25% Trypsin-EDTA (Gibco/Life Technologies, Carlsbad, CA; 25200-072) and 
reseeding at a split ratio of 1:4. J82 (HTB-1), RT4 (HTB-2), and HT-1376 (CRL1472) 
cell lines were obtained from ATCC and cultured in DMEM (Sigma-Aldrich, St. Louis, 
MO; D5523) with 10% (v/v) FBS (Gibco/Invitrogen, Grand Island, NY; 16000-044), 5 
mg/ml glucose (Fisher Scientific, Pittsburgh, PA; D16-500), and 1x nonessential amino 
acids (Gibco/Invitrogen, Grand Island, NY; 11140). Cells were given fresh media every 
2-3 days or upon confluency and were subcultured at a split ratio of 1:3 upon confluency 
using 0.25% Trypsin-EDTA (Gibco/Life Technologies, Carlsbad, CA; 25200-072). 
MCF-10A cells were obtained from ATCC and were grown in 1:1 DMEM 
(Sigma-Aldrich, St. Louis, MO; D5523): Ham’s F12 Nutrient Mixture (Sigma-Aldrich, 
St. Louis, MO; N6760). Culture media was supplemented with 5% (v/v) fetal bovine 
serum (FBS) (Gibco/Invitrogen, Grand Island, NY; 16000-044), 20 ng/ml epidermal 




PHG0311), 0.5 μg/ml hydrocortisone (Sigma-Aldrich, St. Louis, MO; HO135), 10 μg/ml 
insulin (Sigma-Aldrich, St. Louis, MO; I2643), and 0.1 μg/ml cholera toxin (Sigma-
Aldrich, St. Louis, CA; C8052). Cells were supplied with fresh media every 3 days or 
upon confluency. Subculture was also completed upon confluency using 0.25% Trypsin-
EDTA (Gibco/Life Technologies, Carlsbad, CA; 25200-072) and reseeding at a split ratio 
of 1:10. MDAMB-231, Hs578T, T47D, and MCF-7 cells were obtained from ATCC and 
cultured using G-5 media consisting of DMEM (Sigma-Aldrich, St. Louis, MO; D5523) 
with 5% (v/v) FBS (Gibco/Invitrogen, Grand Island, NY; 16000-044) and 5 mg/ml 
glucose (Fisher Scientific, Pittsburgh, PA; D16-500). Cells were supplied with fresh 
media every 2 days or upon confluency. Subculture was also competed upon confluency 
using 0.25% Trypsin-EDTA (Gibco/Life Technologies, Carlsbad, CA; 25200-072) and 
reseeding at a split ratio of 1:10. 
2.2 Transformation of UROtsa Cells with As3+ and Cd2+ 
In order to evaluate the impact of As3+ and Cd2+ exposure on bladder cancers, a 
model of metal-induced bladder cancers was made using the UROtsa bladder epithelial 
cell line. In order to create this model, UROtsa cells were transformed by feeding cells 
with media containing either 1 μM NaAsO2 (Sigma-Aldrich, St. Louis, MO) or 1 μM 
CaCl2 (Sigma-Aldrich, St. Louis, MO). This exposure was continued and cells were 
evaluated every 5 passages for the ability to form colonies in soft agar (Sens et al. 2004; 
Cao et al. 2010; Somji et al. 2010). Once transformed with either metal, microarray 
analysis was previously competed using the GeneChip human Genome U133 plus 2.0 




Genome Explorations (Menphis, TN) in order to evaluate differential gene expression 
patterns in response to either As3+ or Cd2+ (Talaat et al. 2011).  
Previously, transformed UROtsa cell lines were used to generate heterotransplant 
tumors. Using the transformed cell lines, 1 x106 cells were injected either subcutaneously 
or intraperitoneally into nude mice. As formerly described, tumors were allowed to grow 
for 10 weeks following subcutaneous injection or 53 days following intraperitoneal 
injection, at which time mice were sacrificed and the tumors collected for analysis (Cao 
et al. 2010; Somji et al. 2010). The UROtsa cell lines were also used to derive spheroids 
as previously described (Slusser-Nore et al. 2016). Briefly, the transformed UROtsa cell 
lines were cultured in ultra-low attachment flasks and supplied with serum-free medium 
for 8 days. UROtsa spheroids were then harvested and processed for RNA and protein. 
2.3 Exposure of UROtsa Cells to As3+ and Cd2+ 
 In order to determine whether AGR2 is induced by either As3+ or Cd2+, time 
course exposures were done using UROtsa cells. To determine the effect of As3+, UROtsa 
cells were exposed to 2, 4, or 6 μM NaAsO2 (Sigma-Aldrich, St. Louis, MO) for 72 
hours. For Cd2+, UROtsa cells were exposed to 1, 2, or 4 μM CdCl2 (Sigma-Aldrich, St. 
Louis, MO) for up to 72 hours. For both As3+ and Cd2+ exposures, cells were harvested at 
12, 24, 48, and 72 hours and processed to obtain RNA and protein. 
2.4 Transformation of MCF-10A Cells with As3+ and Cd2+ 
 In order to evaluate the impact of As3+ and Cd2+ on breast cancers, a model of 
metal-induced breast cancers was made using the MCF-10A breast epithelial cell line. In 
order to create this model, MCF-10A cells were transformed by feeding cells with media 




Aldrich, St. Louis, MO). This exposure was continued and cells were evaluated every 5 
passages for the ability to form colonies in soft agar (Soh et al. 2011). Once transformed 
with either metal, microarray analysis was competed using GeneChip human Genome 
U133 plus 2.0 arrays (Affymetrix, Santa Clara, CA) and was analyzed for global gene 
expression by Genome Explorations (Memphis, TN) in order to evaluate differential gene 
expression patterns in response to either As3+ or Cd2+. 
2.5 Exposure of MCF-10A Cells to As3+ and Cd2+ 
 In order to determine whether AGR2 is induced by either As3+ or Cd2+, time 
course exposures were done using MCF-10A cells. To determine the effect of As3+, 
MCF-10A cells were exposed to 1, 8, or 16 μM NaAsO2 (Sigma-Aldrich, St. Louis, MO). 
For Cd2+, MCF-10A cells were exposed to 2, 4, or 8 μM CdCl2 (Sigma-Aldrich, St. 
Louis, MO) for up to 48 hours. For both As3+ and Cd2+ exposures, cells were harvested at 
12, 24, 36, and 48 hours and processed to obtain RNA and protein.  
2.6 AGR2 Transfection of MCF-10A Cells 
A construct containing AGR2 was made using the 6.2 V5-DEST vector and 
obtained from Invitrogen (Carlsbad, CA). Amplification of the construct was 
accomplished by transforming the plasmid into E. coli cells (OneShot-OmniMax 2-T1R; 
Invitrogen/Life Technologies, Carlsbad, CA; C8540-03). Successfully transformed 
colonies were selected using LB (Fisher, Pittsburgh, PA; BP1427-500) agar (Fisher, 
Pittsburgh, PA; BP1423-500) plates with 100 μg/ml ampicillin. Transformed bacterial 
colonies were inoculated into liquid LB and bacterial stocks were amplified and pelleted. 
Plasmid preparation was done using the Endo-Free Maxi Prep Kit (Qiagen, Germantown, 




England BioLabs, Ipswich, MA; R0517S) and purified using the GeneClean Kit (MPBio, 
Santa Ana, CA; 111102-400). Stable transfection of 2 μg blank vector or 2 μg AGR2 
vector was accomplished via electroporation using the Amaxa Cell Line Nucleofector Kit 
L (Lonza, Allendale, NJ; VCA-1005). Colonies were selected using 20 μg/μl blasticidin S 
HCl (BSD) (Gibco/Life Technologies, Carlsbad, CA; A11139-03). 
2.7 Cell Viability and Doubling Times 
 In order to determine the effects of AGR2 expression on MCF-10A cell growth, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction and 
wound healing assays were used. The MCF-10A model was used for these assays, 
including As3+ and Cd2+-transformed cell lines as well as MCF-10A cells transfected with 
either blank 6.2 V5-DEST vector or a 6.2 V5 vector containing the coding regions of the 
AGR2 gene. For proliferation, MTT assays were performed. Cells were seeded in 6-well 
plates and allowed to grow for up to 6 days. Plates of cells were taken daily and exposed 
to 100 mg/ml MTT (Sigma-Aldrich, St. Louis, MO; M5655) for 3.5 hours. Cells were 
then rinsed twice with phosphate buffered saline and then with 1 ml acidic propanol. 
Optical density was evaluated at 570 nm and data were used to calculate doubling times 
for each cell line. 
2.8 Wound/Scratch Assays 
 Cells were grown to confluency in 6-well plates and a scratch was made created 
using a 100 μl pipette tip. The wells were washed twice with phosphate buffered saline 
and fresh media was added to the cells. Images were taken right after the addition of 
media (0 hours) and after 4, 8, and 12 hours in order to evaluate the levels of cell 




2.9 RNA Isolation and Real-time RT-PCR 
Cells were harvested using a cell scraper and pelleted via centrifugation. Total 
RNA isolation was performed using TRI REAGENT (Molecular Research Center, Inc. 
Cincinnati, OH; TR 118) according to supplied protocol and as previously outlined by 
this laboratory (Somji et al., 2006). RNA was converted to cDNA using the iScript cDNA 
Synthesis Kit (Bio-Rad Laboratories, Hercules, CA; 170-8890). Real-time PCRs were 
run using iTaq Universal SYBR Green Superrmix (Bio-Rad Laboratories, Hercules, CA; 
172-5124) or IQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA; 
1708882). For Anterior Gradient 2 (AGR2) and Estrogen Receptor 1 (ESR1 or ERα), 
QuantiTect Primer Assays (Qiagen) were obtained for the determination of mRNA 
expression. These primer assays were Hs_AGR2_1_SG and Hs_ESR1_1_SG 
respectively. Identical cycling parameters were used for AGR2 and ESR1 primers. 
Cycling was done with denaturation at 95 ̊C for 15 sec, annealing at 62 ̊C for 45 sec, and 
extension at 72 ̊C for 30 sec. To aid in validation of construct expression, primers were 
designed for the V5 tag of the 6.2 V5 DEST vector and obtained from Invitrogen (Grand 
Island, NY). Primer sequences for the V5 tag were sense, 
TTCGAAGGTAAGCCTATCCCT, and antisense, AGTCATTACTAACCGGTACGC. 
Cycling parameters for V5 primers were denaturation at 95 ̊C for 15 sec, annealing at 
55 ̊C for 45 sec, and extension at 72 ̊C for 30 sec. 
2.10 Protein Extraction and Quantitation 
 Whole cell lysates were prepared using 1x SDS (Life Technologies, Carlsbad, 




Quantification of protein levels in each sample was done using the BCA assay kit 
obtained from Thermo-Fisher Scientific (Waltham, MA; 23228 and 1859678).  
2.11 Collection and Preparation of Spent Media 
 MCF-10A cells were cultured for 24 hours in serum free media in a T75 flask 
prior to confluency. Spent media was collected and the cell monolayer was harvested 
using a cell scraper. Spent media was prepared using Amicon® Ultra-15 centrifugal filters 
with Ultracell® 3 membranes (EMD Millipore, Billerica, MA;UFC900308). Media was 
centrifuged for 1 hour at 4 ̊C and 3700 relative centrifugal force (RCF) to concentrate 
media samples. Total protein concentrations were then determined using the BCA assay 
reagents (Thermo-Fisher Scientific, Waltham, MA; 23228 and 1859678). 
2.12 Western Blot Analysis 
Protein expression levels were determined using 10 or 20 μg of total cellular protein on 4-
20% Mini-PROTEAN TGX Stain-Free Gels (Bio-Rad Laboratories, Hercules, CA; 456-
8094). AGR2 protein levels were detected using a rabbit monoclonal antibody to AGR2 
(Abcam, Cambridge, MA; ab76473) at a 1:5,000 dilution and secondarily anti-rabbit IgG, 
HRP-Linked antibody (Cell Signaling, Boston, MA; 7074S) at a 1:2,400 dilution. Beta 
Actin protein levels were detected using a mouse monoclonal antibody to Beta-Actin 
(Abcam, Cambridge, MA; ab8226) at a 1:1,000 dilution and secondarily anti-mouse IgG, 
HRP-Linked antibody (Cell Signaling, Boston, MA; 7076S) at a 1:2,400 dilution. 
Biotinylated markers were detected using anti-biotin-linked antibody (Cell Signaling, 
Boston, MA; 7075S) at a 1:1,200 dilution. Antibody visualization was accomplished 





Table 1 – Western Antibody Sources 
Antibody Target Company Catalog Number 
AGR2 Abcam ab76473 
Biotin secondary Cell Signaling 7075S 
Mouse secondary Cell Signaling 7076S 
Rabbit secondary Cell Signaling 7074S 
β-Actin Abcam ab8226 
 
2.13 Immunofluorescent Staining of MCF-10A Cell Lines 
 MCF-10A cells were cultured on 12 mm glass coverslips in 24-well plates until 
confluent. Cells were then rinsed twice with DMEM:F12 media containing no phenol red 
and fixed in 3.7% paraformaldehyde (Polysciences, Warrington, PA; 18814-10) for 20 
min. 0.1 M NH4Cl (Sigma, St. Louis, MO; A-5666) was used for 15 min to quench free 
aldehyde groups and cells were permeabilized for 30 min using 0.3% Triton-X100 
(Fisher Scientific, Pittsburg, PA; BP151-100). Cells were incubated for 1 hour in AGR2 
primary antibody (Abcam, Cambridge, MA; ab76473) at a 1:600 dilution. Alexa 
Fluor®488 goat anti-rabbit IgG secondary antibody (Life Technologies, Carlsbad, CA; 
A11008) was used for 1 hour at a 1:1,000 dilution. Stained coverslips were then mounted 
in ProLong® Diamond Antifade Mountant with DAPI (Life Technologies, Carlsbad, CA; 
P36971).  Anterior gradient 2 immunofluorescence was visualized using a Leica DM5500 
Q TCS SPE confocal microscope. Z-slice images were captured and processed using 
LAS-X software. 
2.14 Immunohistochemical Analysis of Tumors and Tumor Specimens  
UROtsa heterotransplant tumors were formalin-fixed and embedded in paraffin 
prior to immunohistochemical analysis. Formalin-fixed paraffin-embedded breast and 
bladder cancer specimens were also used for immunohistochemical analysis. Specimens 




medical waste. These archival specimens contained no patient identifiers and are in the 
exempt category for human research.  Sections of transplanted tumors were cut into 3-5 
µm thick slices for use in immunohistochemical protocols. The primary antibody used 
was AGR2 (Abcam, Cambridge, MA; ab76473) at a 1:500 dilution for 30 minutes.  
Immunohistochemical staining was performed on Leica Bond-Max Automated IHC 
Staining System (Leica, Bannockburn, IL). Paraffin sections were processed starting with 
deparaffinization and ending with counterstaining by hematoxylin according to the 
manufacturer’s recommended program with modification. Bond Polymer Refine 
Detection (Leica, DS9800) was used as the main reagent in the automatic staining 
process. Briefly, the major steps include deparaffinization, antigen retrieval in Bond 
Epitope Retrieval Solution 1 (Leica, Catalog No AR9961) for 20 min, peroxide block for 
5 min, incubation with primary antibodies for 30 min at room temperature, incubation 
with Post Primary for 10 min, incubation with polymer for 10 min, visualization with 
3,3’-diaminobenzidine (DAB) for 10 min, and counterstaining with hematoxylin for 5 
min. Slides were rinsed in distilled water, dehydrated in graded ethanol, cleared in 
xylene, and coverslipped. The presence and degree of immunoreactivity in the specimens 
was judged by two pathologists.  The scale used was 0 to +3 with 0 indicating no 
staining, +1 staining of mild intensity, +2 staining of moderate intensity, and +3 staining 
of strong intensity. All immunohistochemical preparation, staining, and analysis were 
performed by Dr. Xudong Zhou. 
2.15 Treatment of MCF-10A Cells with 5-Azacytidine and MS-275 
 MCF-10A cells were fed with media containing 1, 3, or 10 μM Entinostat (MS-




(Sigma-Aldrich, St. Louis, MO) for 72 hours. Following exposure, cells were harvested 
to obtain cell pellets which were processed to obtain RNA and protein as described 
above.  
2.16 Statistical Analysis 
 Statistical analysis was conducted using GraphPad Prism® 5.0 software. Real-time 
PCR and western I.O.D. analysis was analyzed in triplicate and evaluated using an 
unpaired T-test when comparing two samples. When comparing multiple samples either 
one-way analysis of variance (ANOVA) with a post-hoc Tukey multiple comparison test 
or two-way ANOVA with Bonferroni post-hoc tests were used for statistical analysis. 
Asterisks are used to denote statistically significant differences compared to the control 






3.1 Expression of AGR2 in Bladder Cancers  
Analysis of AGR2 expression in urothelial cancers by Ho and coworkers (2016) 
showed strong staining of AGR2 in normal urothelium, but in urothelial cancer AGR2 
expression was lost, with only 25% of primary tumors observed to retain expression in a 
cohort of lymph node positive cases. The present study examined the 
immunohistochemical localization and expression of AGR2 in a small sample set: five 
specimens of benign urothelium; four cases of low grade urothelial cancer; five cases of 
high grade, non-invasive urothelial cancer; and, five cases of high grade, muscle invasive 
urothelial cancer. Immunohistochemical staining, imaging, and analysis were done by 
Xudong Zhou. All five specimens of normal urothelium showed moderate cytoplasmic 
staining of AGR2 throughout the urothelium, with lesser staining in the umbrella cells 
(black arrow) forming the outer layer of the bladder epithelium (Figure 2 A). This is not 
surprising as bladder epithelia have been shown to express AGR2 (Ho et al. 2016). The 
underlying smooth muscle cells showed no staining for AGR2. As illustrated for one 
specimen with moderate/heavy staining for AGR2, all four cases of low grade urothelial 
cancer stained positive for AGR2. The staining of the four specimens varied between 
moderate and strong and over 80% of the urothelial cancer cells in all specimens were 
positive for the expression of AGR2 (Figure 2 B). The expression of AGR2 in non-




to 80% of the urothelial cells (one specimen illustrated as Figure 2 C) and two cases with 
moderate staining but with only 5% of the urothelial cells staining positive for AGR2 
(one specimen illustrated as Figure 2 D). The expression of AGR2 was also variable in 
high grade, muscle invasive urothelial cancer. Three specimens of high grade, muscle 
invasive bladder carcinoma were negative for the expression of AGR2 (two specimens 
illustrated in Figure 2 E and F with 2 F having an internal control with staining for benign 
urothelium). The other two specimens showed weak to moderate staining for AGR2 in 
30% of the cells (Figure 2 G) and the other moderate to strong staining in over 80% of 
the cells (Figure 2 H). These data demonstrate variability in AGR2 expression among 
high-grade and invasive urinary carcinomas. A summary of AGR2 staining in bladder 
cancers specimens is provided in Table 2. In this table, the intensity of AGR2 staining in 
benign epithelium (if present) was scored. Also evaluated were the intensity of AGR2 
staining in tumor cells and the overall percentage of tumor cells stained for AGR2 for 
each slide evaluated. Overall, these results indicate that AGR2 expression can be lost in 





Figure 2 – AGR2 Staining in Urothelial Carcinomas. A: Normal bladder urothelium. 
B: Low grade non-invasive urothelial carcinoma of the ureter. C: High grade non-
invasive urothelial carcinoma of the bladder. D: High grade non-invasive urothelial 
carcinoma with focal areas suspicious for invasion. E-H: High grade invasive urothelial 




Table 2 – Summary of AGR2 Staining in Specimens of Urothelial Carcinoma. 
Tumor type, AGR2 staining intensity, and percentage of cells positive for AGR2 staining 
for each tumor evaluated. LG – low grade, HG – high grade, LG ca. w/f HG – low grade 
carcinoma with focal high grade, NA – not applicable (no benign or tumor cells present), 





Benign Urothelium 3+ NA NA 
Benign Urothelium 2+ NA NA 
LG carcinoma 3+ 2-3+ 80 
LG carcinoma NA 3+ 80 
LG ca. w/f HG NA 2-3+ 80 
HG Noninvasive NA 2-3+ 5 
HG Noninvasive NA 2-3+ 70 
HG Noninvasive NA 3+ 80 
HG Noninvasive NA 3+ 80 
HG Invasive 3+ - - 
HG Invasive NA 2-3+ 30 
HG Invasive 3+ - - 
HG Invasive 3+ - - 
HG Invasive NA - - 
HG Invasive NA 3+ 80 
LG Benign Tissues NA 3+ 80 
 
3.2 Expression of AGR2 in UROtsa Cells Transformed with As3+ or Cd2+ 
 As this laboratory is primarily interested in evaluating the effect that As3+ and 
Cd2+ have on various cancers, a model for As3+ and Cd2+-induced urothelial cancers has 
previously been established using the UROtsa bladder epithelial cell line. Briefly, the 
UROtsa cell line was exposed to 1 μM NaAsO2 or 1 μM CdCl2, resulting in the formation 
of six As3+ and seven Cd2+-transformed UROtsa cell lines. These UROtsa cell lines have 
been shown to be a good model for heavy metal induced urothelial carcinomas (Rossi et 
al. 2001). Gene expression changes in the transformed UROtsa cell lines were evaluated 
using microarray analysis and compared to that of the non-transformed UROtsa cell line. 




was AGR2, which was induced 4.87 fold over parent (Garrett et al. 2014). Anterior 
gradient 2 expression in the bladder is of interest as it has been identified as a biomarker 
for advanced bladder cancers when secreted in the blood or urine (Ho et al. 2016). The 
next goal for this study was to evaluate AGR2 expression in the UROtsa model of heavy 
metal induced bladder cancers. Real-time PCR and western analysis were used to 
determine AGR2 expression in As3+ and Cd2+-transformed UROtsa cell lines. The data 
showed that AGR2 is significantly upregulated in four of the As3+ and six of the Cd2+-
transformed UROtsa cell lines (Figure 3 A and D). Western analysis also confirmed an 
increase in AGR2 protein in the majority of the As3+ and Cd2+-transformed cell lines 
(Figure 3 B-C and E-F). Complicating the analysis is that the western blotting for AGR2 
exhibited evidence of post-translational modification, seen as two separate bands and/or 
as smeared bands. This requires using a generous area when integrating optical density 
for further analysis rather than a tight area around a single band, affecting the integrated 
optical density (I.O.D.) analysis of western blotting for AGR2 (Figure 3 B-C and E-F). 
This has been observed in other publications studying AGR2 and may indicate the O-
glycosylation of secreted AGR2. At least one previous study demonstrated that the O-
glycosylation of AGR2 may affect extracellular functions (Clarke, Rudland, and 
Barraclough 2015). This secondary or smeared band therefore makes it challenging to 
visualize the full impact of the changes to AGR2 protein expression which may account 
for some of the variability between mRNA and protein expression. Results indicate that 
AGR2 expression increases following transformation of UROtsa cells with As3+ or Cd2+. 
Transformed UROtsa cell lines were injected into nude mice and allowed to form 




expression using real-time PCR. Only two of the As3+ heterotransplant tumors retained 
significantly increased AGR2 expression (Figure 4 A). Four of the Cd2+ heterotransplant 
tumors maintained significantly increased AGR2 expression (Figure 4 B). 
Immunohistochemical staining of As3+ and Cd2+ heterotransplant tumors was done to 
further evaluate AGR2 expression. Results showed that heterotransplant tumors arising 
from arsenic-transformed UROtsa cell lines #1, #3, and #6 exhibited AGR2 staining 
though all tumors had a small population of cells with moderate staining (Figure 5). In 
tumors derived from the Cd2+-transformed UROtsa cell lines, AGR2 staining was 
strongest in cell lines #2, #5, and #6. Once again, all tumors exhibited a population with 
moderate AGR2 staining (Figure 6). A summary of the immunohistochemical staining is 
provided in Table 3. These results show that AGR2 expression is induced in urothelial 
cancers arising from As3+ and Cd2+-transformed cells. In turn, this suggests that As3+ and 





Figure 3 – AGR2 Expression in As3+ and Cd2+-transformed UROtsa Cell Lines. A: 
Real-time PCR analysis of AGR2 expression in UROtsa cells transformed with As3+. B: 
Western analysis of AGR2 in As3+-transformed UROtsa cell lines. C: I.O.D. analysis of 
western data in B, plotted as AGR2/β-Actin. D: Real-time PCR analysis of AGR2 
expression in UROtsa cells transformed Cd2+. E: Western analysis of AGR2 in Cd2+-
transformed UROtsa cell lines. F: I.O.D. analysis of western data in E, plotted as 
AGR2/β-Actin. *** denotes (p < 0.001) and ** (p < 0.01) statistically significant 
difference from parent UROtsa cells. Real-time and western I.O.D. data is plotted as the 





Figure 4 – AGR2 Expression in Heterotransplant Tumors from As3+ and Cd2+-
transformed UROtsa Cell Lines. A: Real-time PCR analysis of AGR2 expression in 
heterotransplant tumors arising from As3+-transformed UROtsa cell lines injected into 
nude mice. B: Real-time PCR analysis of AGR2 expression in heterotransplant tumors 
arising from Cd2+-transformed UROtsa cell lines injected into nude mice. Real-time data 






Figure 5 – AGR2 Staining in UROtsa As3+ Heterotransplants. A: UROtsa As #1 
tumor. B: UROtsa As #2 tumor. C. UROtsa As #3 tumor. D: UROtsa As #4 tumor. E: 






Figure 6 – AGR2 Staining in UROtsa Cd2+ Heterotransplants. A: UROtsa Cd #1 
tumor. B: UROtsa Cd #2 tumor. C: UROtsa Cd #3 tumor. D: UROtsa Cd #4 tumor. E: 





Table 3 – Summary of AGR2 Staining in UROtsa Heterotransplant Tumors. 
Intensity of AGR2 staining and percentage of cells positive for AGR2 staining. 
 AGR2 
Group Intensity Percentage 
UROtsa As #1 2+ 10 
UROtsa As #2 1-2+ <5 
UROtsa As #3 2-3+ 50 
UROtsa As #4 1+ <5 
UROtsa As #5 2+ 5 
UROtsa As #6 2+ 20 
UROtsa Cd #1 1-2+ <5 
UROtsa Cd #2 3+ 70 
UROtsa Cd #3 2-3+ 20 
UROtsa Cd #4 2-3+ 30 
UROtsa Cd #5 2-3+ 60 
UROtsa Cd #6 3+ 70 
UROtsa Cd #7 2+ 10 
LG urothelial carcinoma 3+ 80 
 
3.3 Expression of AGR2 in UROtsa Cells Exposed to As3+ or Cd2+ 
 Next, this study sought to evaluate whether AGR2 expression can be induced by a 
short-term exposure to either As3+ or Cd2+. UROtsa cells were exposed to 2, 4, or 6 μM 
NaAsO2 or 1, 2, or 4 μM CdCl2 for up to 72 hours. Expression of AGR2 increased within 
48 hours in response to As3+ exposure (Figure 7 A). For the most part, significant 
induction of AGR2 in response to Cd2+ exposure was not seen. Notable increases in 
AGR2 expression did occur by 48 hours with 2 μM Cd2+ and at 72 hours with 1 μM Cd2+. 
Significant decrease in AGR2 expression occurred at 48 hours with exposure to 4 μM 
Cd2+. These decreases are likely attributable to the toxicity exhibited by the UROtsa cells 
at this concentration of Cd2+ (Figure 7 B). Results suggest that there is little to no 





Figure 7 – AGR2 Expression in UROtsa Cells Exposed to As3+ or Cd2+. A: Real-time 
PCR analysis of AGR2 expression in UROtsa cells exposed to 2, 4, or 6 μM As3+ for up 
to 72 hours. B: Real-time PCR analysis of AGR2 expression in UROtsa cells exposed to 
1, 2, or 4 μM Cd2+ for up to 72 hours. *** denotes (p < 0.001), ** (p < 0.01), and * (p < 
0.05) statistically significant difference from untreated UROtsa cells harvested with each 





3.4 Expression of AGR2 mRNA in Cancer-Initiating-Cells (CICs) Isolated from the 
As3+ and Cd2+-transformed UROtsa Cell Lines 
 
This laboratory has extended the UROtsa model of As3+ and Cd2+-induced bladder 
cancers to include spheroids isolated from the transformed cell lines by culturing the cell 
lines in serum-free media and in low attachment flasks. Previous studies by this group 
shown that these spheroids express high levels of aldehyde dehydrogenase 1 (ALDH1) 
and form subcutaneous tumor transplants identical to those of the As3+ and Cd2+-
transformed cells (Sandquist et al. 2016; Slusser-Nore et al. 2016).  This fulfills the 
requirement that these spheroids represent cancer-initiating cells (CICs).  The expression 
of AGR2 mRNA was determined on total RNA isolated from the spheroids isolated from 
the As3+ and Cd2+-transformed cell lines and all the spheroids were shown to express 
AGR2 mRNA (Figure 8 A and B). Tumors generated from the CICs in the above two 
studies (Sandquist et al. 2016; Slusser-Nore et al. 2016) for two of the As3+-transformed 
cell lines and two of the Cd2+-transformed cell lines were examined for their expression 
of AGR2 protein using immunohistochemistry. The staining for AGR2 was similar to 
that found above for tumors generated directly from the cultured cell lines; cytoplasmic, 
focal, and associated with the more undifferentiated cells of the tumor (Figure 9). The 
results showed that between 20 to 30% of the tumor cells of all four tumor transplants 






Figure 8 – AGR2 Expression in CICs Derived from As3+ and Cd2+-transformed 
UROtsa Cell Lines. A: Real-time PCR analysis of AGR2 expression in spheroids 
derived from the As3+-transformed UROtsa cell lines. B: Real-time PCR analysis of 
AGR2 expression in spheroids derived from the Cd2+-transformed UROtsa cell lines. *** 
denotes a (p < 0.001), ** (p < 0.01), and * (p < 0.05) statistically significant difference 
from spheroids derived from the non-transformed parental UROtsa cell line. Real-time 






Figure 9 – AGR2 Staining in UROtsa-derived CICs. A: UROtsa As #1 spheroid 
derived tumor. B: UROtsa As #3 spheroid derived tumor. C: UROtsa As #6 spheroid 









Table 4 – Summary of AGR2 Staining in Heterotransplant Tumors from UROtsa-
derived CICs. Tumor type, AGR2 staining intensity, and percentage of cells positive for 
AGR2 staining for each tumor evaluated. LG – low grade. 
  AGR2 
Group Tumor Type Intensity Percentage 
UROtsa As #1 Spheroid 3+ 20 
UROtsa As #3 Spheroid 2-3+ 30 
UROtsa As #6 Spheroid 2-3+ 20 
UROtsa Cd #1 Spheroid 2-3+ 30 
UROtsa Cd #4 Spheroid 3+ 30 
LG urothelial carcinoma NA 3+ 80 
 
3.5 AGR2 Expression in Urothelial Carcinoma Cell Lines 
 
 After evaluating AGR2 expression in As3+ and Cd2+-transformed UROtsa cell 
lines and corresponding heterotransplant tumors, this study next sought to evaluate AGR2 
expression in three commercially-available urothelial carcinoma cell lines. Real-time 
PCR and western analysis were used to determine AGR2 expression in the J82 (HTB-1), 
RT4 (HTB-2), and HT-1376 (CRL1472) cell lines, which had been previously obtained 
from ATCC. The J82 cell line was obtained from a 58-year old Caucasian male with 
transitional cell carcinoma. The RT4 cell line was isolated from a transitional cell 
papilloma in a 63-year old Caucasian male. The HT-1376 cell line was isolated from a 
58-year old Caucasian female with grade 3 urothelial carcinoma. Results showed that 
AGR2 mRNA is expressed in all three urothelial carcinoma cell lines but is most highly 
expressed in the RT4 and HT-1376 cell lines (Figure 10 A). Western analysis also 
showed that AGR2 is expressed in all three of the urothelial carcinoma cell lines and that 
it has the greatest expression in the RT4 cell line (Figure 10 B and C). These results 
demonstrate that AGR2 expression is present in bladder cancer cell lines.  
 Next, this study determined whether AGR2 expression remains elevated in tumors 




carcinoma cell lines by injecting each cell line subcutaneously or intraperitoneally into 
nude mice. Slides made from the isolated tumors were stained for AGR2 expression 
using immunohistochemical techniques. Results indicate positive AGR2 staining in 
subcutaneous and intraperitoneal tumors arising from the HT-1376 cell line (Figure 11 A 
and B). Tumors derived from subcutaneous or intraperitoneal injection of the J82 cell line 
did not exhibit staining for AGR2 (Figure 11 C and D). Strongly positive AGR2 staining 
was seen in subcutaneous tumors derived from the RT4 cell line (Figure 11 D and F). An 
intraperitoneal tumor derived from the RT4 cell line exhibited strong AGR2 staining in 
tumor cells (Figure 11 G). A further summary of these results is shown in Table 5. These 
results indicate that only the HT-1376 and RT4 derived tumors were able to maintain 






Figure 10 – AGR2 Expression in Urothelial Carcinoma Cell Lines. A: Real-time PCR 
analysis of AGR2 expression in urothelial carcinoma cell lines. Real-time data is plotted 
as the mean ± SEM of triplicate determinations. B: Western blot analysis of AGR2 in 







Figure 11 – AGR2 in Heterotransplants from Urothelial Carcinoma Cell Lines. A: 
Subcutaneous HT-1376 tumor. B: Intraperitoneal HT-1376 tumor. C: Subcutaneous J82 
tumor. D: Intraperitoneal J82 tumor. E: Subcutaneous RT4 tumor. F: Subcutaneous RT4 




Table 5 – Summary of AGR2 Staining in Heterotransplants from Urothelial 
Carcinoma Cell Lines. Tumor type, AGR2 staining intensity, and percentage of cells 
positive for AGR2 staining for each tumor evaluated.  
  AGR2 
Cell Line Tumor Type Intensity Percentage 
HT-1376 Subcutaneous 3+ 30 
HT-1376 Intraperitoneal 3+ 40 
J82 Subcutaneous - 0 
J82 Intraperitoneal - 0 
RT4 Subcutaneous 3+ 100 
RT4 Intraperitoneal 3+ 100 
 
3.6 Expression of AGR2 in MCF-10A Cells Transformed with As3+ or Cd2+ 
 In order to better understand the impact of As3+ and Cd2+ on breast cancers, a 
model for heavy metal-induced breast cancer has previously been established using the 
MCF-10A breast epithelial cell line (Soh et al. 2011). Previous microarray analysis and 
subsequent studies on how As3+ and Cd2+ affect the expression of AGR2 in the UROtsa 
model of heavy metal-induced bladder cancers prompted the question of whether similar 
effects might be seen in the MCF-10A model. In order to see if AGR2 may also serve as 
a biomarker for heavy metal-induced breast cancers, the expression of AGR2 was 
determined in the MCF-10A parent and the As3+ and Cd2+-transformed cells using real-
time PCR and western analysis. Real-time PCR analysis showed a significant increase in 
AGR2 expression in the As3+-transformed MCF-10A cell line compared to non-
transformed MCF-10A cells. A significant decrease in AGR2 expression was seen in the 
Cd2+-transformed MCF-10A cell line (Figure 12 A). Western blotting of whole cell 
lysates was used to evaluate AGR2 protein expression in the transformed MCF-10A cell 
lines. The results also indicated a significant increase in AGR2 protein expression 
following As3+-transformation and a significant decrease in AGR2 protein following 




These results indicate that AGR2 expression is increased in response to transformation 
with As3+ but not Cd2+ in MCF-10A cells.  
 
Figure 12 - Expression of AGR2 mRNA and Protein in As3+ and Cd2+-transformed 
MCF-10A Cells. A: Real-time PCR analysis of AGR2 mRNA in As3+ and Cd2+-
transformed MCF-10A cells. ***Denotes a statistically significant difference from MCF-
10A parent cells (p < 0.001). Real-time data is plotted as the mean ± SEM of triplicate 
determinations. B: Western blot analysis of AGR2 and protein in As3+ and Cd2+-







3.7 Expression of AGR2 in MCF-10A Cells Exposed to As3+ or Cd2+ 
After having established that As3+-transformation can result in increased AGR2 
expression, this study next sought to determine whether AGR2 expression is induced by 
exposure to As3+ or Cd2+. In order to evaluate the effect that As3+ exposure has on AGR2 
expression, MCF-10A cells were exposed to 4, 8, or 16 μM NaAsO2 for up to 48 hrs. 
Cells were harvested 12, 24, 36, and 48 hours following treatment and analyzed by real-
time PCR and western analysis to determine AGR2 expression. Data indicate that AGR2 
expression was significantly increased in response to As3+ exposure. By 36 hours, 2, 3.6, 
and 4.9 fold increases in AGR2 mRNA was seen at 4, 8, and 16 μM As3+ exposure 
respectively (Figure 13 A). Furthermore, western blotting followed by I.O.D. analysis 
indicated as much as a 7.5 fold increase in AGR2 protein expression after 36 hours 
exposure to 16 μM As3+ (Figure 13 B and C). Additionally, this study sought to establish 
whether Cd2+ is capable of inducing AGR2 expression. To accomplish this, MCF-10A 
cells were exposed to 2, 4, or 6 μM CdCl2 for 12, 24, 36, or 48 hours and were analyzed 
using real-time PCR for AGR2 expression. The data obtained indicated that there was a 
transient increase in the expression of AGR2 at 12 hour of exposure with 4 μM Cd2+, 
however the levels went down by 24 hours (Figure 14). These results demonstrate that 
As3+ is capable of inducing AGR2 expression in MCF-10A cells while AGR2 expression 





Figure 13 - Expression of AGR2 mRNA and Protein in As3+-exposed MCF-10A 
Cells. MCF-10A cells were exposed to 4, 8, or 16 μM As3+ for 12, 24, 36, or 48 hrs and 
the expression level of AGR2 was determined. A: Real-time PCR analysis. Asterisks 
denote a statistically significant difference from 0 μM As3+ within each time point with * 
(p < 0.05), ** (p < 0.01) and *** (p < 0.001). Real-time data is plotted as the mean ± 
SEM of triplicate determinations. B: Western blot analysis of AGR2 expression in MCF-







Figure 14 - Expression of AGR2 mRNA in Cd2+-exposed MCF-10A Cells. Real-time 
PCR analysis of AGR2 transcripts in MCF-10A cells exposed to 2, 4, or 6 μM Cd2+ for 
12, 24, 36, or 48 hrs. Asterisks denote a statistically significant difference from 0 μM 
Cd2+ within each time point with * (p < 0.05), ** (p < 0.01) and *** (p < 0.001). Real-
time data is plotted as the mean ± SEM of triplicate determinations. 
 
3.8 AGR2 Expression in Breast Cancer Cell Lines 
Previous studies have demonstrated that AGR2 expression is correlated to breast 
cancers, specifically subtypes which commonly exhibit poor prognosis (Fritzsche et al. 
2006; Barraclough et al. 2009; Lacambra et al. 2015) . Since the expression of AGR2 is 
correlated to the ERα status (Thompson and Weigel 1998; Innes et al. 2006; Salmans, 
Zhao, and Andersen 2013), this study sought to determine AGR2 expression in 
commercially available breast cancer cell lines that are widely used as in-vitro models of 
breast cancer. For this purpose, breast cancer cell lines known to have different ERα 
expression profiles were utilized. Real-time PCR and western analysis were used to 




ERα-positive (T47D and MCF-7) breast cancer cell lines. Results showed the greatest 
increase of AGR2 mRNA expression in the T47D breast cancer cell line, moderate 
increases in the MCF-7 and MDAMB cell lines, and essentially undetectable AGR2 
expression in Hs578T cells (Figure 15 A). Western blotting analysis showed a similar 
trend for AGR2 protein expression, with the greatest expression in the T47D cell line. 
The MDAMB-231 and MCF-7 cell lines also exhibited increased AGR2 protein while 
AGR2 was not detectable in the Hs578T cell line using western blotting (Figure 15 B and 
C). These results suggest that AGR2 is highly expressed in a well-known ERα-positive 






Figure 15 - Expression of AGR2 mRNA and Protein in Breast Cancer Cell Lines. A: 
Real-time PCR analysis of AGR2 expression in breast cancer cell lines. Real-time data is 
plotted as the mean ± SEM of triplicate determinations. B: Western blot analysis of 
AGR2 in breast cancer cell lines. C: Integrated optical density (I.O.D.) analysis of 




3.9 Role of ERα in MCF-10A Cells 
Anterior gradient 2 expression has been shown to be influenced by estrogen 
receptor (ERα) status in breast cancers (Thompson and Weigel 1998; Innes et al. 2006; 
Salmans, Zhao, and Andersen 2013). This study next sought to further investigate 
whether ERα has a role impacting AGR2 expression in the MCF-10A breast cell model. 
Normally MCF-10A cells are known to be ERα-negative, however the possibility for 
MCF-10A cells to begin expressing ERα has been demonstrated (Lane et al. 1999). With 
this in mind real-time PCR analysis was used to evaluate ERα (ESR1) expression in 2 
ERα-negative (MDAMB-231 and Hs578T) and 2 ERα-positive (T47D and MCF-7) 
breast cancer cell lines as well as in parent and As3+ and Cd2+-transformed MCF-10A cell 
lines. While ERα expression was confirmed in both ERα-positive breast cancer cell lines, 
high ERα-expression was not seen in any of the MCF-10A cell lines (Figure 16). These 
data suggest that the expression of AGR2 in MCF-10A cells is most likely due to ERα-
independent mechanisms. This is especially true when evaluating the As3+ and Cd2+-
transformed MCF-10A cell lines. The non-transformed MCF-10A cell line did exhibit a 
low level of ERα expression, therefore the possibility of ERα influences on AGR2 





Figure 16 – ERα Expression in Breast Cancer and MCF-10A Cell Lines. Real-time 
PCR analysis of AGR2 transcripts in breast cancer cell lines (MDAMB, Hs578T, T47D, 
and MCF-7) as well as MCF-10A cell lines transformed with As3+ or Cd2+. Real-time data 
is plotted as the mean ± SEM of triplicate determinations.  
 
3.10 Effect of the Overexpression of AGR2 on MCF-10A Cell Proliferation 
 The next goal of this study was to investigate the functional impact that AGR2 
expression has in breast tissue, especially as those functions may have significant impact 
on the outcome of AGR2-expressing breast cancers. An AGR2-overexpressing MCF-10A 
cell line was created which could be used to further elucidate the functions of AGR2 in 
breast epithelia. Real-time PCR and western analysis were used to confirm AGR2 
overexpression (Figure 17). These data indicate that an AGR2-overexpressing MCF-10A 
cell line was generated and that this cell line will be useful for evaluating the functional 




As AGR2 expression has been known to affect cell proliferation and has been 
previously associated with metastasis (Liu et al. 2005; Ramachandran et al. 2008; Wang, 
Hao, and Anson W. Lowe 2008), the next goal of this project was to evaluate the growth 
and migration potential of MCF-10A cells transformed with As3+ or transfected with 
AGR2. In order to determine the effect of As3+ or Cd2+-transformation on MCF-10A cell 
growth rates, MTT assays were utilized. The results obtained indicated a significant 
increase in proliferation for As3+-transformed MCF-10A cells compared to the non-
transformed MCF-10A cell line (Figure 18). Wound/scratch assays were performed on 
MCF-10A cell lines in order to determine the migration potential of the cells. Images 
were collected and analyzed from just after scratching (0 hr) and from 4, 8, and 12 hours 
later. Wound closure rates were then determined in order to evaluate migration into the 
wound. MCF-10A cells transformed with As3+ exhibited a 70.62% wound closure rate, 
significantly increased over parent MCF-10A cells (48.03%) or Cd2+-transformed MCF-
10A cells (57.37%) (Figure 19). These results demonstrate that As3+-transformed cells 
had an increased growth rate and migration potential when compared to the parent MCF-
10A cells and the Cd2+-transformed cells, suggesting a more tumorigenic phenotype in 
As3+-transformed MCF-10A cells. While it may seem tempting to correlate the changes 
in growth and migratory potential to the increased AGR2 expression exhibited by the 
As2+-transformed MCF-10A cell line, there are any number of potential mechanisms to 
which these effects may be attributed. Further studies will be needed to determine which 
mechanism(s) may be involved. 
We also wanted to determine if overexpression of AGR2 in MCF-10A cells 




the growth rate, MTT assays were performed on the MCF-10A cells transfected with 
either the blank 6.2 V5-DEST vector or with an AGR2-containing construct. The data 
obtained shows that overexpression of AGR2 in MCF-10A cells can increase their 
growth rate when compared to cells transfected with the blank vector alone (Figure 20). 
This project also sought to determine whether overexpression of AGR2 would affect the 
migration potential of the MCF-10A cells transfected with AGR2 in a wound scratch 
assay. Results show that overexpression of AGR2 in MCF-10A cells results in an 
increase in the wound closure rate when compared to the blank vector (Figure 21). In 
conclusion, these data suggest that overexpression of AGR2 can affect the growth rate 
and migration potential of cells, hence its expression may have an effect on the metastatic 
potential of breast cancer cells. To further verify the effect of AGR2 on the proliferation 
and migration of MCF-10A cells, further experiments would need to be completed. These 
experiments might include the knock-down of AGR2 expression in the As3+-transformed 





Figure 17 - Expression of AGR2 mRNA and Protein in MCF-10A Cells Transfected 
with AGR2. A: Real-time PCR analysis of AGR2 mRNA. B: Western analysis of AGR2 






Figure 18 – Effect of As3+ and Cd2+-transformation on the Growth Rate of MCF-10A 
Cells. The growth rates were determined by measuring the capacity of the cells to reduce 
MTT to formazan. The cells were allowed to grow for 6 days and the ability of the cells 
to reduce MTT was determined every day. All experiments were done in triplicates and 






Figure 19 – Effect of As3+ and Cd2+-transformation on the Migration of MCF-10A 
Cells. MCF-10A parent and transformed cell lines were subjected to wound scratch assay 
and migration of the cells was determined after 4, 8 and 12 hours. Percent wound 





Figure 20 - Effect of AGR2 Expression on the Growth Rate of MCF-10A Cells 
Transfected with the Blank Vector or the AGR2 Gene. The growth rates were 
determined by measuring the capacity of the cells to reduce MTT to formazan. The cells 
were allowed to grow for 6 days and the ability of the cells to reduce MTT was 
determined every day. All experiments were done in triplicates and shown is the mean ± 








Figure 21 - Effect of AGR2 Expression on MCF-10A Cell Migration. MCF-10A cells 
were transfected with AGR2 or a blank vector and were scratched at confluency. The 
ability of the cells to grow and migrate into the wound was determined after 4, 8 and 12 
hours of incubation. Percent wound closures were calculated and are presented beneath 




3.11 Localization of AGR2 in MCF-10A Cells 
Normally AGR2 is seen localized to the endoplasmic reticulum and may be 
secreted outside of the cell (Park et al. 2009; Bergström et al. 2014). In the case of AGR2 
expression, it is of great interest to determine localization as it has been demonstrated that 
AGR2 localization impacts its function (Gupta, Dong, and Lowe 2012; Chevet et al. 
2013; Tsuji et al. 2014; Fessart et al. 2016; Li et al. 2016). There remains a need to better 
understand how the cellular or extracellular localization of AGR2 impacts its function as 
very few studies have addressed this question so far. This study next sought to determine 
the localization of AGR2 in MCF-10A cells using immunofluorescence microscopy and 
representative images are shown in Figure 22. Parent MCF-10A cells showed weak to no 
AGR2 staining (Figure 22 A). While the AGR2-transfected MCF-10A cell line had cells 
exhibiting the strongest AGR2 staining, there were smaller clusters of cells with this 
strong staining rather than exhibiting staining throughout the population of cells. The 
intense staining had a very apparent web-like appearance which was slightly more 
localized to near the nucleus, indicative of endoplasmic reticulum localization (Figure 22 
B). Staining in the As3+ and Cd2+-transformed MCF-10A cell lines showed populations of 
cells with moderate to strong AGR2 staining also consistent with localization to the 
endoplasmic reticulum (Figure 22 C and D). Overall, these results indicated that AGR2 is 
mainly localized to the endoplasmic reticulum in each of the MCF-10A cell lines 
evaluated. No apparent localization of AGR2 to secretory vesicles was seen which would 
have exhibited a more widespread and punctate staining throughout the cytoplasm. This 
suggests that AGR2 is mainly localized in the endoplasmic reticulum in MCF-10A cells 





Figure 22 – AGR2 Localization in MCF-10A Cell Lines. Images of AGR2 
immunofluorescence in MCF-10A cell lines. A: Parent MCF-10A B: AGR2-transfected 
MCF-10A C: As3+-transformed MCF-10A D: Cd2+-transformed MCF-10A. Blue – DAPI 
(nuclear) staining, Green – AGR2  
 
3.12 Secretion of AGR2 in MCF-10A Cell Lines 
Secretion of AGR2 has been shown to result in the initiation and progression of 
various cancers, including that of the prostate (Ramachandran et al. 2008) and to promote 
tumorigenic characteristics in MCF-7 cells (Li et al. 2015; Li et al. 2016). Recently it was 
demonstrated that AGR2 secretion may serve as a useful biomarker for bladder cancers 




cell line, the next aim was to verify whether AGR2 is secreted in MCF-10A cells. While 
AGR2 did not appear to be localized to secretory vesicles, this possibility could not be 
completely discounted. In order to further establish whether AGR2 is secreted, 
conditioned media and cell monolayers were collected from As3+-transformed and 
AGR2-transfected MCF-10A cells. Western analysis was performed in order to 
determine whether AGR2 was secreted and conditioned media from T47D cells was used 
as a positive control for secreted AGR2. Data indicated that AGR2 is not secreted in any 
of the MCF-10A cell lines (Figure 23). This suggests that secretion does not have a 
significant impact on AGR2 function in the MCF-10A cell line. 
 
Figure 23 – AGR2 Secretion in MCF-10A cells. Western analysis of AGR2 expression 
in cell lysate and conditioned media from T47D and MCF-10A cells transfected with 
AGR2 or transformed by As3+.  
 
3.13 Expression of AGR2 in Breast Cancers 
 The next goal was to determine the impact of AGR2 in breast cancers and to 
evaluate whether AGR2 expression correlates with tumor type or grade. A panel of breast 
cancers archived in paraffin blocks was used for immunohistochemical staining and 
consisted of ductal carcinoma in situ (DCIS) and grade 1, 2, and 3 infiltrating ductal 
carcinoma (IDC). Ductal carcinoma in situ is a subtype of breast cancers in which tumors 




Infiltrating ductal carcinoma, also known as invasive ductal carcinoma, occurs when 
breast cancers which originated in the mammary duct have progressed through the milk 
duct and has potential to spread throughout mammary tissues or to metastasize to lymph 
nodes. Tumors that are determined histologically to be well differentiated are classified 
as Grade 1. Similarly grade 2 tumors are moderately differentiated and grade 3 represents 
poorly differentiated tumors (AJCC 2010).  
Specimens were stained for AGR2 expression using immunohistochemical 
techniques in order to determine whether AGR2 expression correlates to stage or 
progression of breast cancers. Normal breast tissues exhibited AGR2 staining in lobular 
and ductal epithelial cells, with no observed staining in the surrounding myoepithelial 
cells (Figure 24 A and B). Low grade DCIS exhibited moderate AGR2 staining while 
high grade DCIS showed strong staining for AGR2 (Figure 24 C and D). Grade 1 IDCs 
exhibited moderate to strong AGR2 staining (Figure 24 E and F). Grade 2 IDC exhibited 
AGR2 staining in tumor cells, either in scattered tumor cells or localized in cancer nests 
(black arrow) while benign ducts exhibited no AGR2 staining (Figure 25 A and B). One 
section with both grade 2 IDC and intermediate grade DCIS exhibited strong AGR2 
staining in the affected duct (DCIS – white arrow) and in the IDC nests (black arrow) to 
either side the affected duct. No AGR2 staining was observed in the surrounding 
myoepithelial cells (Figure 25 C). In benign breast cells from the same slide as Figure 25 
C, results showed luminal epithelial cells (black arrow) positive for AGR2 staining while 
outer myoepithelial cells did not show AGR2 staining (Figure 25 D). Another grade 2 
IDC also exhibited strong AGR2 staining in cancer cells (Figure 25 E). One slide of 




were moderately positive for AGR2 (Figure 25 F). Another grade 3 IDC exhibited 
strongly AGR2 stained cancer nests (black arrow) with no AGR2 staining in two benign 
ducts (white arrows) (Figure 25 G). Diffuse and strong positive AGR2 staining was also 
seen in another grade 3 IDC (Figure 25 H). In summary, AGR2 staining of at least 
moderate degree was seen in all tumor samples, as demonstrated in DCIS and Grade 1 
IDC (Figure 24). The intensity of staining increased with increasing grades of breast 
tumors, as seen in grade 2 and 3 IDCs (Figure 25). In most instances, the myoepithelial 
cells surrounding the tumor did not exhibit significant AGR2 staining. Overall, this data 
shows that increased AGR2 expression is correlated with higher grades of IDC, 
suggesting that AGR2 is a biomarker for breast cancers. 
The previously mentioned slides were also stained for ERα expression in an 
attempt to discern whether hormone receptor status may correlate with AGR2 expression 
and tumor subtype. Table 6 summarizes the results as determined by two pathologists. 
Nine of the seventeen lesions evaluated demonstrated strong AGR2 and strong ERα 
staining, with all but one of the grade 3 IDCs exhibiting strong staining for both. Of the 
seven grade 2 IDCs, four exhibited strong staining for both AGR2 and ERα and two 
showed moderate staining for both. There was one instance of no to weak staining for 
both AGR2 and ERα. One of the grade 1 IDC lesions exhibited strong staining for AGR2 
and ERα while the other lesion was weakly stained for AGR2 but strongly stained for 
ERα. Neither the high grade or low grade DCIS lesion evaluated exhibited moderate or 
strong ERα staining while the high grade DCIS showed strong AGR2 positivity. Benign 




that there may be a correlation between AGR2 expression and the ERα status of the 
tumor.  
  
Figure 24 – AGR2 Staining in Benign, DCIS, and Grade 1 Infiltrating Ductal 
Carcinoma of the Human Breast. A: Human benign breast tissue. B: Normal human 







Figure 25 – AGR2 Staining in Grade 2 and 3 Infiltrating Ductal Carcinoma of the 
Human Breast. A-B: Grade 2 IDCs. C: Grade 2 IDC and intermediate grade DCIS. D: 





Table 6 – Immunostaining of AGR2 and ERα in Human Breast Carcinomas. 
Summarizes AGR2 and ERα staining data from DCIS and IDC lesions as seen in Figure 
24 and Figure 25. G1 – Grade 1, G2 – Grade 2, G3 – Grade 3, HG – High Grade, LG – 
Low Grade  
Lesion 
AGR2 ERα 
Intensity % Intensity % 
IDC-G3 3+ 90 3+ 90 
IDC-G3 3+ 90 3+ 90 
IDC-G3 3+ 90 2+ 80 
IDC-G3 3+ 90 2-3+ 60 
IDC-G3 3+ 80 2-3+ 80 
IDC-G3 2-3+ 50 3+ 90 
IDC-G2 3+ 90 3+ 90 
IDC-G2 3+ 90 3+ 90 
IDC-G2 3+ 90 3+ 80 
IDC-G2 2-3+ 80 3+ 90 
IDC-G2 2-3+ 70 2-3+ 70 
IDC-G2 3+ 60 2+ 60 
IDC-G2 2+ <5 2+ 20 
IDC-G1 3+ 90 3+ 90 
IDC-G1 2+ 20 2-3+ 80 
DCIS-HG 3+ 80 - - 
DCIS-LG 1-2+ 10 2+ 30 
Benign 2-3+ 50 3+ 50 
 
3.14 Epigenetic Regulation of AGR2 in MCF-10A and Breast Cells 
 At least one study has demonstrated that AGR2 expression can be regulated by 
DNA methylation, increasing AGR2 expression and producing more aggressive ovarian 
cancer phenotypes (Hirst and Marra 2009; Sung et al. 2014). This suggests a possible 
mechanism for the induction of AGR2 expression in breast cancers. It was therefore 
decided that it would be beneficial to further investigate epigenetic modifications as a 
possible mechanism by which As3+ could induce AGR2 expression. DNA methylation is 
considered to be associated with the decreased expression of gene transcription therefore 
genes regulated by DNA methylation should exhibit increased expression in the presence 




Marra 2009). Histone deacetylases (HDACs) are responsible for removing acetyl groups 
from histones, resulting in the repression of gene expression (Struhl 1998). Inhibitors of 
HDACs, such as Entinostat (MS-275), can be used in an attempt to restore gene 
expression when regulation occurs via histone acetylation. MCF-10A cells were exposed 
to 1, 3, or 10 μM MS-275 or either 1 or 3 μM 5-AZC for 72 hours. Data showed 
increasing AGR2 expression with increasing doses of both HDAC and DMT inhibitors 
(Figure 26). This suggests that both histone acetylation and DNA methylation play roles 
in the regulation of AGR2 transcription in MCF-10A cells.  
We next sought to determine whether histone acetylation or DNA methylation are 
also active in regulating AGR2 expression in commercially available breast cancer cell 
lines. In order to determine whether AGR2 expression is under epigenetic control, 
MDAMB-231 and Hs578T cells were exposed to 1, 3, or 10 μM MS-275, or either 1 or 3 
μM 5’-azacytidine (5-AZC) for 72 hours. Real-time PCR analysis was used to determine 
AGR2 mRNA expression. Data indicated that AGR2 expression was not as highly 
induced in MDAMB-231 cells as in MCF-10A cells, suggesting that AGR2 expression is 
still partially regulated by both histone acetylation and DNA methylation in MDAMB-
231 cells (Figure 27 A). Hs578T, cells may be partially regulated by histone acetylation 
but did not appear to be regulated by DNA methylation (Figure 27 B). Overall, these data 
suggest that histone acetylation and DNA methylation may have roles in the regulation of 
AGR2 transcription in various breast cancers. Further study is necessary in order to verify 
the specific roles that histone acetylation and DNA methylation may play in AGR2 
regulation. Both 5-AZC and MS-275 are known to affect global epigenetic regulatory 




further studies are performed, it is possible that the effect of histone acetylation and DNA 
methylation on AGR2 seen in the data presented in this study represent indirect effects. 
 
Figure 26 – MCF-10A Expression of AGR2 in Response to MS-275 or 5-AZC. Real-
time PCR analysis of AGR2 transcripts in MCF-10A cells exposed to MS-275 (1, 3, or 10 
μM) or 5-AZC (1 or 3 μM) for 72 hours. Asterisks denote a statistically significant 
difference from untreated MCF-10A cells with * (p < 0.05), ** (p < 0.01) and *** (p < 






Figure 27 – Expression of AGR2 in Response to MS-275 or 5-AZC in Breast Cancer 
Cell Lines. Real-time PCR analysis of AGR2 transcripts in A: MDAMB and B: Hs578T 
cells exposed to MS-275 (1, 3, or 10 μM) or 5-AZC (1 or 3 μM) for 72 hours. Asterisks 
denote a statistically significant difference from untreated control (Ctl) cells with * (p < 
0.05), ** (p < 0.01) and *** (p < 0.001).  Real-time data are plotted as the mean ± SEM 







4.1 AGR2 in the Bladder 
This laboratory has examined the expression of AGR2 in a small set of archival 
specimens of low grade and high grade urothelial cancers and found benign urothelium 
and low grade tumors to have the most pronounced expression of AGR2, with high grade 
non-invasive and high grade invasive cancers having absent or lower expression. This 
finding is in agreement with the only previous study to examine AGR2 expression in 
urothelial cancer (Ho et al. 2016). The expression of AGR2 in breast cancer correlates 
with lower tumor grade, epidermal growth factor receptor negativity, and estrogen 
receptor alpha (ERα) positivity (Fletcher et al. 2003; Innes et al. 2006). In breast cancer, 
high AGR2 expression is associated with poor outcome in ERα-positive cancers and 
hormonally treated breast cancers (Fritzsche et al. 2006; Barraclough et al. 2009; Hrstka 
et al. 2010; Lacambra et al. 2015). An analysis of AGR2 mRNA expression in prostate 
cancer also showed AGR2 to be upregulated in all tumors in general compared to benign 
tissues, but with low grade tumors and prostatic intraepithelial neoplasia (PIN) lesions 
having the highest expression of AGR2 compared to control (Bu et al. 2011). In addition, 
transcripts of AGR2 were higher in Gleason score (GSC) 6 tumors when compared to 
GSC 8-10 tumors, suggesting expression is decreased as grade increases. An analysis of 
AGR2 expression in three commonly utilized human bladder cancer cell lines showed the 




 While in general AGR2 expression appears to be lost or decreased in higher grade 
tumors, the previous studies in breast, prostate and urothelial cancer also suggested a 
poor prognosis when AGR2 expression does remain elevated in high grade cancers.  In 
prostate cancer, AGR2 expression has been shown to be elevated in circulating tumor 
cells in the plasma from patients with metastatic prostate cancer (Kani et al. 2013).  
Anterior gradient 2 expression in circulating cells was most pronounced in tumors with 
neuroendocrine or anaplastic features with an aggressive clinical phenotype without 
elevated circulating prostate specific antigen (PSA) levels. As noted above for breast 
cancers, high AGR2 expression correlates to a poor prognosis in ERα-positive breast 
cancers, and as detailed in the introduction, findings in urothelial cancer showed tumor 
invasion fronts of primary tumors and lymph nodes from many of these primary tumors 
to express AGR2. The findings in urothelial cancer suggest the hypothesis that AGR2 
expression may favor the local spread of the tumor.  
In an attempt to gain insight into AGR2 expression in urothelial cancer, AGR2 
expression was explored employing As3+ and Cd2+-transformed UROtsa cells since the 
expression of AGR2 could be examined during cell transformation in vitro and in in vivo 
tumor transplants derived from these cells. Overall, the expression of AGR2 in the 
independent isolates of the As3+ and Cd2+-transformed cells and derived tumors was 
highly variable. The expression of AGR2 mRNA and protein was variable within the 
independent isolates of the As3+ and Cd2+-transformed cell lines, with five of six of the 
Cd2+ and four of seven of the As3+-transformed cell lines having mRNA levels 
significantly elevated over control. The corresponding expression of the AGR2 protein 




four of the six As3+ and in six of the seven Cd2+-transformed cell lines. The expression of 
AGR2 mRNA and protein was also highly variable in the tumor transplants and AGR2 
expression showed little or no relationship to the amount of AGR2 expressed in the 
initiating cell line. The % of AGR2 staining cells in the tumor transplants from the 
independently generated As3+ and Cd2+-transformed UROtsa cell lines varied from 5 to 
70%. This demonstrates the ability of As3+ and Cd2+ to stimulate AGR2 expression in 
urothelial cells.  
This complements studies that have demonstrated the ability of AGR2 to have a 
role in stimulating tumor cell proliferation and metastasis as well as studies that have 
demonstrated the ability of AGR2 to impact the formation of xenograft tumors. One 
study demonstrated the potential for AGR2 to induce metastasis and tumor formation 
when transfection of a construct containing a cDNA sequence identical to that of AGR2 
into Rama 37 rat mammary cells promoted a metastatic phenotype when injected in 
syngeneic rats (Liu et al. 2005). Anterior gradient 2 was also demonstrated to increase 
migration and xenograft tumor growth in two esophageal adenocarcinoma cell lines using 
both in vitro and in vivo assays (Wang, Hao, and Anson W. Lowe 2008). Another set of 
in vitro studies found that silencing of secreted AGR2 is capable of decreasing the ability 
of prostate cancer cells to grow, survive, and undergo invasion, suggesting that AGR2 
plays a role in these cellular functions in prostate cancer (Ramachandran et al. 2008). 
Similarly, another group demonstrated that knockdown of AGR2 expression in cell lines 
isolated from ERα-positive breast cancers reduced the ability of the cell lines to grow, 
progress through the cell cycle, and undergo anchorage-independent growth (Vanderlaag 




expression and that exposure to extracellular AGR2 can stimulate increased growth, 
migration, and progression through the cell cycle as well as EMT in MCF-7 cells (Li et 
al. 2015; Li et al. 2016).   
 In an attempt to define a reason for the above heterogeneity in AGR2 expression, 
AGR2 was determined in CICs isolated as spheroids from the individual cell lines. As 
detailed in the results the spheroids fulfill the requirement to be defined as CICs. The 
results show that CICs isolated from the As3+ and Cd2+-transformed cell lines all have 
expression, be it variable, of AGR2 mRNA. This appears to be one of the first 
observations that AGR2 is expressed in CICs isolated from transformed cells in culture. 
In addition, the tumors derived from the CICs isolated from two each of the As3+ and 
Cd2+-transformed cell lines demonstrated moderate to strong staining of AGR2 in 20 to 
30% of the cells. Taken together the findings suggest the following evolution of AGR2 
expression from cell culture to tumor transplants. First, the expression of AGR2 mRNA 
and protein in the As3+ and Cd2+-transformed cell cultures, while interesting, probably 
has very little to do with the subsequent expression of AGR2 in the tumor transplants. 
The rationale being that the expression of AGR2 is dictated by the small sub-population 
of CICs and not the overall AGR2 signature of the entire culture. In the two previous 
studies with CICs from the As3+ and Cd2+-transformed cells, the expression in the tumor 
transplant recapitulated the expression in the CICs and not the entire culture (Sandquist et 
al. 2016; Slusser-Nore et al. 2016). This suggests that the tumor transplants are initiated 
by CICs that express the AGR2 gene. One may also speculate that AGR2 might enhance 
tumor initiation since AGR2 expression has been suggested in an analysis of clinical 




Second, the expression pattern of AGR2 in tumor cells within the tumor 
transplants would be consistent with AGR2 being present at the early stages of tumor 
growth and then becoming dormant as the tumor undergoes differentiation into higher 
grade tumor cells. This is suggested by the fact that previous studies have shown tumor 
transplants derived from these cell lines undergo squamous differentiation, producing a 
tumor with a more undifferentiated cell population and one comprised of cells with 
squamous character (Sens et al. 2004; Cao et al. 2010; Somji et al. 2010). Squamous 
differentiation in urothelial cancer is associated with a poor prognosis (Logothetis et al. 
1989; Martin, Jenkins, and Zuk 1989; Akdaš and Türkeri 1991; Frazier et al. 1993). In 
the present study the differentiated squamous components of the tumor transplants were 
negative for the expression of AGR2 while the more undifferentiated components stained 
positive for AGR2. These observations are consistent with AGR2-expressing CICs 
initiating the tumor transplant, undergoing initial proliferation to form the tumor, and a 
loss of AGR2 as the tumor differentiates/progresses to a higher grade, more aggressive 
cell type. What the study does not answer is if the undifferentiated AGR2 staining 
component is driving continued tumor growth or if the AGR2 positive cells would 
disappear from the tumor if growth was continued by serial passage. Overall, the results 
show that CICs derived from the UROtsa model system provide are useful in helping to 
define the role of AGR2 expression from tumor initiation through serial transplant of the 
tumor, which could eventually further the study of tumor initiation and metastasis to 






4.2 AGR2 in the Breast 
 Breast cancer has become a focus for cancer research and represents one of the 
greatest health concerns for women in developed countries. One area of breast cancer 
research warranting further study is the significance of AGR2 expression in the breast. 
Even with recent advances, there remains a need to discover more accurate and 
informative biomarkers for breast cancers, not only to aid in early detection but to allow 
for more informed treatment decisions based on biomarkers which might more accurately 
predict a given patient’s prognosis. Previously this lab has observed that the proto-
oncogene AGR2 exhibits increased expression following As3+ or Cd2+-transformation of 
UROtsa cells, based on microarray analysis (Garrett et al. 2014). This prompted the 
further evaluation and characterization of AGR2 expression in a model of As3+ and Cd2+-
induced breast cancers which was created using the MCF-10A breast epithelial cell line. 
Preliminary experiments demonstrated that AGR2 expression increases following 
transformation of MCF-10A cells with As3+ and that AGR2 expression is induced by 
exposure to As3+ in MCF-10A cells. These results add to previous studies linking As3+ 
exposure to breast cancer risk (Xu, Erik J Tokar, and Waalkes 2014). 
A possible connection of AGR2 expression to ERα status is also of interest as 
AGR2 expression has previously been shown to be responsive to the presence of estrogen 
and ERα (Thompson and Weigel 1998; Innes et al. 2006; Salmans, Zhao, and Andersen 
2013). For example, it has been previously established that AGR2 expression predicts 
poor prognosis when highly expressed in ERα-positive breast cancers (Barraclough et al. 
2009; Hrstka et al. 2010; Lacambra et al. 2015). Other experiments have also indicated 




this area has not been well studied (Hrstka et al. 2010). In this study, AGR2 expression 
was demonstrated in the ERα-positive T47D and MCF-7 cell lines and in the ERα-
negative MDAMB cell line, indicating that AGR2 expression is common in some 
subtypes of breast cancers. In this study it was further demonstrated that ERα is not 
highly expressed in the MCF-10A cell lines, showing that As3+ and Cd2+-transformed 
MCF-10A cells remained ERα-negative. This suggests that any effect seen as a result of 
AGR2 expression in transformed MCF-10A cells may be due to ERα-independent 
mechanisms or functions. This also suggests an explanation for why AGR2 functions and 
responses in the MCF-10A model may differ from what has been previously 
demonstrated in literature involving AGR2.  
 Anterior gradient 2 expression has previously been known to impact cell 
functions with potential to contribute to both tumorigenesis and to the progression of 
cancers, particularly metastasis (Liu et al. 2005; Wang, Hao, and Anson W. Lowe 2008; 
Park et al. 2011; Tsuji et al. 2014; Li et al. 2015; Fessart et al. 2016; Li et al. 2016). In 
breast and other cancers, AGR2 expression has also been shown to enable cancer 
progression and tumor cell survival (Vanderlaag et al. 2010; Dumartin et al. 2011; 
Brychtova et al. 2014). Here this study has demonstrated that As3+-transformation is 
capable of increasing cell growth and migration in MCF-10A cells, suggesting that As3+ 
exposure can lead to cellular responses which may result in tumorigenesis or metastasis. 
While not fully established in this study, data suggest the possibility that the mechanism 
by which this process occurs could involve the induction of AGR2 expression as this 
study demonstrated the ability of As3+ to induce AGR2 expression. In this study, it was 




MCF-10A cells transfected with the AGR2 gene. This suggests a role for AGR2 in 
conferring properties to breast epithelia which have been known to contribute to tumor 
formation, progression, and metastasis (Wang, Hao, and Anson W. Lowe 2008; Di Maro 
et al. 2014). In short, the induction of AGR2 expression, by As3+ among other means, 
may stimulate growth in breast epithelia resulting in tumor formation and eventual 
metastasis.  
The present study has demonstrated that AGR2 is localized mainly to the 
endoplasmic reticulum in the MCF-10A cell lines, which is consistent with the previously 
established AGR2 role as a PDI in breast epithelia. Functioning as a PDI, responding to 
endoplasmic reticulum stress, is the most well-understood role which has been 
established so far for AGR2 in previous studies (Higa et al. 2011). As part of its ability to 
function as a PDI, it has been shown that AGR2 can be secreted when the KTEL 
endoplasmic reticulum retention sequence is lost (Park et al. 2009; Gupta, Dong, and 
Lowe 2012; Bergström et al. 2014). This prompted the determination of whether or not 
AGR2 is being secreted in the MCF-10A model. Data revealed that AGR2 is not secreted 
by MCF-10A cells, even when AGR2 expression is increased due to As3+-transformation 
or AGR2 transfection into the cell. These data further suggest that AGR2 is primarily 
functioning within the endoplasmic reticulum in MCF-10A cells.  
Previous work has established that AGR2 expression is a predictor of poor 
prognosis in breast cancers and is associated mainly with more advanced breast cancers 
(Fritzsche et al. 2006; Barraclough et al. 2009; Hrstka et al. 2010). Evaluation of AGR2 
expression in breast carcinoma specimens of low and high grade DCISs and grade 1, 2, 




strongest staining seen in the higher grades of IDC. This strengthens the data supporting 
AGR2 expression as a useful biomarker for advanced breast cancers. 
 Little is known regarding the mechanisms that regulate AGR2 expression at this 
time. If the regulation of AGR2 were better understood, it could lead to potential targets 
for future cancer therapies aimed at inhibiting the progression or metastasis of AGR2 
expressing cancers. As this project has demonstrated that As3+ exposure can induce 
AGR2 expression in MCF-10A cells, a potential mechanism by which AGR2 expression 
is regulated was evaluated. One potential regulatory mechanism for gene expression that 
has been previously associated with AGR2 expression involves DNA methylation (Sung 
et al. 2014). Another common mechanism for the epigenetic regulation of gene 
expression involves histone acetylation (Struhl 1998). After evaluating AGR2 expression 
in response to a HDAC inhibitor (MS-275) and an inhibitor of DNA methylation (5-
AZC), data reveal that AGR2 expression in MCF-10A cells is regulated, at least partially, 
by these epigenetic mechanisms.  
From this study, a picture begins to form which allows for an improved level of 
understanding regarding AGR2 expression and regulation, particularly in relation to those 
functions with the potential to affect cancers of the bladder and breast. It is possible that 
As3+ exposure induces AGR2, potentially through epigenetic means such as histone 
acetylation and DNA methylation. This induction of AGR2 in turn may stimulate the 
formation, proliferation, and eventual migration of affected epithelial cells in the breast or 
bladder, among others. This study demonstrates the potential usefulness of further 
research aimed at increasing the current understanding of the regulation and involvement 
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